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ABSTRACT 
Cytomegaloviruses are highly host specific, and murine cytomegalovirus (MCMV) has 
been widely used as a model for studying human cytomegalovirus (HCMV) infections to 
overcome the difficulty of experimentation with HCMV in vivo. The ability to manipulate the 
viral genome and introduce specific mutations into viral genes should facilitate the 
investigation of mechanisms governing cytomegalovirus host specificity. Our laboratory has 
utilized a modified MCMV genome lacking a SwaI site to construct recombinant MCMVs 
through homologous recombination. However, it was not known whether this modification of 
the MCMV genome by removing the SwaI site would affect the biological properties of 
MCMV, or whether the SwaI mutation could be reversed should the need arose. To this end, 
two recombinant bacterial artificial chromosomes, pMCMV_ETwt and pMCMV_ETSwa-*, 
were constructed and characterized by restriction endonuclease analysis, demonstrating that 
only the expected genome modifications were present. Recombinant viruses were then 
reconstituted in tissue culture and their biological properties were compared to the Smith strain 
of MCMV as well as the parental MCMV_EGFP virus. Viral DNA isolated from infected cells 
showed the expected restriction patterns for MCMV-ETwt and MCMV-ETSwa-. The 
expression of MCMV proteins M112-113, ppM44 and gB, representative of those expressed in 
the early, delayed early, and late phases of infection, respectively, did not differ significantly 
between the recombinant viruses or the Smith strain of MCMV. In addition, virus growth in 
permissive Balb/3T3 cells at both low and high multiplicities of infection, and semi-permissive 
COS-1 cells at a high multiplicity of infection showed growth kinetics or patterns of infection 
that were similar to the Smith strain of MCMV. Results from these preliminary experiments 
suggested that the modification of the MCMV genome by removal of the SwaI site did not 
appear to affect the biological properties of MCMV in vitro. Furthermore, analysis of 
MCMV_ETwt demonstrated that we could reconstitute the SwaI site in the MCMV genome if 
necessary, resulting in a virus that should be identical to the Smith strain of MCMV. 
Therefore, these results suggest that the SwaI- MCMV genome will enable easier construction 
of recombinant MCMVs with desired alterations in any region of the viral genome. 
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1.0 INTRODUCTION 
1.1  Herpesviruses 
The Herpesvirus family is very large and consists of viruses that are able to infect most 
animal species. Although the herpesvirus family consists of three subfamilies that differ in 
terms of their replication and host range, all herpesviruses share similar virion structure and 
the characteristic of being able to reside in a latent state in their host. 
1.1.1  Classification 
Classification of Herpesviruses into genera is currently based on factors such as 
sequence comparisons (for both genome organization and DNA sequences) and similarities 
between viral proteins.  However, the family members of Herpesviridae were originally 
classified based on their biological properties, resulting in the three subfamilies of 
Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae (Pellett and Roizman, 2007).  
Each subfamily has distinctive characteristics related to viral replication and the host range 
that can be infected. 
The alpha-herpesviruses have a variable host range while the beta- and gamma-
herpesviruses have host ranges limited to their natural hosts.  The three subfamilies also differ 
in terms of their reproductive cycle. Alpha-herpesviruses spread rapidly in cell culture due to 
their short replication cycles whereas beta-herpesviruses spread slowly due to their longer 
replication cycles. Cells infected with alpha-herpesviruses are damaged within a short period 
of time post-infection, whereas cells infected with beta-herpesviruses experience cytomegalia, 
or enlargement.  Although some members of the gamma-herpesviruses are able to cause 
productive infections in epitheliod and fibroblast cells, viruses in this subfamily are usually  
specific for either T or B lymphocytes.  Latent infections are established in sensory ganglia for 
the alpha-herpesviruses, and in secretory glands, lymphoreticular cells, kidneys and other 
tissues for the beta-herpesviruses (Pellett and Roizman, 2007).   
Alpha-herpesviruses include the mammalian Simplexvirus (e.g. herpes simplex virus 
type 1, HSV-1), Varicellovirus (e.g. varicella zoster virus, VZV), the avian Mardivirus (e.g. 
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Gallid herpesvirus 2), and Itovirus (e.g. Gallid herpesvirus 1).  Although this family also 
includes the reptilian herpesviruses, they have not yet been placed into specific genera (Pellet 
and Roizman, 2007). The beta-herpesviruses encompass the genera Cytomegalovirus (Human 
Cytomegalovirus, HCMV), Muromegalovirus (Murine Cytomegalovirus, MCMV), 
Roseolovirus (Human Herpesvirus-6), and putatively, Proboscivirus (Elephant Herpesvirus 1). 
The gamma-herpesviruses contain the genera Lymphocryptovirus (Epstein Barr Virus) and 
Rhadinovirus (Human Herpes Virus-8) although it is proposed that the latter include 
Macavirus and Percavirus. 
1.1.2  Structure and genome organization 
All members of the Herpesviridae family have similar virion structures, which were 
initially used as the basis for classifying a virus as a family member.  The virions range in size 
from 120-260 nm depending on the size of the tegument layer and the morphology of the 
envelope.  Virions include a large number of viral tegument, capsid, and core proteins, as well 
as some host proteins although it is not yet known why this is the case. The viral core contains 
linear double stranded viral DNA, which ranges in size from 120-230 kb depending on the 
virus, and is arranged around the protein core in a toroidal shape. The core is located inside an 
icosahedral nucleocapsid that is 100 nm in size and contains 162 capsomeres.  Surrounding the 
capsid is a tegument layer that varies in thickness, and contrary to its appearance, is an ordered 
structure that contains several proteins. The tegument proteins are critical in helping the virus 
establish productive infection in a new cell by interfering with host functions and activating 
viral gene expression (Pellet and Roizman, 2007). The final component of the herpesvirus 
virion is the envelope, which contains several viral glycoproteins, and its lipid bilayer 
membrane is derived from the host. 
In contrast to the virion structure, the genome organizations of herpesviridae members 
vary significantly.  In very general terms, herpesvirus genomes consist of one or two unique 
sequences flanked by repeated sequences. However, several herpesviruses contain both unique 
long (UL) and unique short (US) regions, flanked with direct and/or inverted terminal and 
internal repeats. In fact, the sizes of the same strain of virus can vary by as much as 10 kb 
based on the number of repeat segments present in the genome (Weir, 1998).  Rearrangement 
of the viral genome is possible when either the US or UL regions (or both) are flanked by 
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inverted repeats. However, if the genome arrangement consists of US and UL regions flanked 
by direct repeats, no rearrangement of the genome is possible. 
1.1.3  Replication 
Herpesvirus replication follows the general stages outlined here. The first stage 
involves the attachment of the virion to specific receptors present on the host cell and 
penetration into the cell mediated by virus surface glycoproteins.  Next, the viral capsid is 
transported to the nucleus where viral DNA is released.  This is where viral DNA replication, 
transcription and assembly of new capsids take place. A common feature of herpesvirus 
infections is the ordered expression of viral genes, ensuring productive infection will occur 
under the right conditions. Immediate-early (IE) genes are the first to be expressed, and their 
gene products activate the expression of early (E) genes, which generally encode proteins 
important for DNA replication. Following viral DNA replication, the late (L) genes are 
expressed, which typically encode structural components of the virion (Greaves and Mocarski, 
1998). Subsequently, viral DNA is assembled into a new capsid, which acquires its envelope 
from the inner nuclear membrane. The enveloped virus is then released into the cytoplasm 
where it undergoes de-envelopment, further modifications to the tegument, and re-
envelopment prior to being released from the cell. 
1.1.4  Latency 
Infection of cells can either result in lytic infection, leading to cell death, or latency, a 
common feature of herpesviruses. Latent viral genomes are not actively replicating and only 
express a subset of viral genes. However they can undergo productive infection upon 
reactivation. As mentioned in a previous section, specific cell types can harbor herpesviruses 
during latency. There is some evidence that reactivation from latency is dependent on 
regulation by host cells (Pellet and Roizman, 2007). 
1.2  Cytomegaloviruses 
Cytomegalovirus (CMV) is a beta-herpesvirus that contains one of the largest viral 
genomes of any mammalian DNA virus. Cytomegalovirus infection in vivo results in 
cytomegaly, which is the enlargement of the infected cell, as well as the presence of inclusions 
in the nucleus. The viral life cycle can take as long as 72 hours to complete in HCMV. The 
CMV genome codes for more than 200 proteins, most of whose functions are unknown. Many 
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of these proteins are dispensable for virus growth in cell culture, but they may play an 
important role during infection of the natural host. Complex interactions between the virus and 
host often determine the outcome of CMV infections. 
There are several types of CMVs, including HCMV, MCMV, Rat CMV (RCMV), 
Simian CMV (SCMV), Guinea Pig CMV, and Equine CMV. Human CMV is a major human 
pathogen, and infects a large proportion of the adult population asymptomatically although it 
can cause severe disease in newborns and immunocompromised individuals. 
1.2.1  Characteristics that make MCMV a good model for HCMV 
Due to the strict species specificity of HCMV, a model of HCMV infection is required 
in order to perform the in vivo testing necessary for the development of vaccines and anti-viral 
drugs. Therefore, a related CMV needs to be used as a model. HCMV is very closely related to 
Chimpanzee CMV, which has HCMV homologs in all open reading frames (Mocarski et al., 
2007). However, due to the impracticalities involved in using primates in most experiments, 
either MCMV or RCMV are commonly used as models for HCMV infection in vivo. In 
particular, MCMV is well suited to being a model since the mouse genome has been 
completely sequenced, and the mouse is the most well characterized laboratory animal in use 
(Rawlinson et al., 1996). Both HCMV and MCMV have characteristics shared by most 
herpesviruses, including their virion structures and the orderly expression of viral genes. 
Furthermore, both viral genomes have been sequenced (Chee et al., 1990; Rawlinson et al., 
1996), and the central regions of the 2 genomes are collinear, with 78 of the predicted open 
reading frames showing sequence similarity between the two viruses (Mocarski and Kemble, 
1996). Human CMV and MCMV have similar mechanisms of pathogenesis in the infected 
host, thereby facilitating the use of MCMV to investigate the biological properties of CMV 
infections (Krmpoti? et. al., 2003). Nevertheless, under certain conditions, MCMV has a less 
restricted host range compared to HCMV and presents an interesting perspective to the study 
of host specificity. 
1.2.2  Genome Organization 
The genome organization of HCMV includes UL and US regions that are flanked by 
their own unique inverted terminal repeat (TRL and TRS) and internal repeat (IRL and IRS) 
sequences (Figure 1.1, Panel B).  This allows both UL and US to be inverted independently to 
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generate 4 possible isomers of the virus (Weir, 1998; Mocarski et al., 2007). In contrast, other 
beta-herpesviruses lack internal repeats (Pellet and Roizman, 2007).  For example, the MCMV 
genome has a long unique sequence with short direct repeats at each terminus (Rawlinson et 
al., 1996; Figure 1.1, Panel A). 
The HCMV genome has around 140 genes that are conserved in all known strains and 
about 80 of these represent genes essential for viral replication in vitro. The MCMV genome 
has around 170 genes, and 78 of these (located in the central 180 kb of the MCMV sequence) 
share significant amino acid homology with HCMV (Rawlinson et al., 1996). In contrast, the 
terminal 24 kb and 27 kb regions of MCMV contain unique genes which are not found in 
HCMV. Both viruses possess a single origin of replication. 
Human CMV genes are labelled from left to right on the prototype form of the viral 
genome according to the region (UL, US, TRL, IRL, TRS or IRS) where the gene is located. The 
numbering system for MCMV genes follows that of HCMV genes for the UL region but 
MCMV homologs to genes in the US, TRL, IRL, TRS or IRS regions do not share the same 
numbering system (Rawlinson et al., 1996). MCMV genes that have HCMV homologs are 
prefixed by an uppercase M. For example, M36 is homologous to HCMV UL36. Those genes 
that are unique to MCMV are prefixed by a lowercase m (e.g. m38.5). In addition, in situations 
where there are additional MCMV genes located between genes homologous to HCMV, 
numbered suffixes are used so that the numbering system can be maintained (e.g. M73.5). 
All herpesviruses contain a set of core genes that tend to be clustered in specific areas 
of the genome. Seven functionally conserved gene blocks are found at similar locations on the 
HCMV and MCMV genomes (Chee et al., 1990; Rawlinson et al., 1996). These include genes 
that encode proteins essential for viral replication: the DNA polymerase (UL54/M54), the 
DNA polymerase accessory factor (UL44/M44), the single-stranded DNA binding protein 
(UL57/M57), and the helicase-primase complex (UL70/M70, UL102/M102, and UL105/M105) 
genes (Rawlinson et al., 1996). Although HSV-1 UL9 is required for replication, there are no 
homologs to this gene in either MCMV or HCMV (Chee et al., 1990; Rawlinson et al., 1996). 
However, all of the additional genes required for HCMV replication, which mainly have 
regulatory roles, are present in MCMV, including the early genes UL112-113/M112-113, 
UL84/M84, and genes located in the major immediate-early (MIE) region (UL122-123/M122-
m123, also known as ie1-ie2/mie1-mie3), the TRS1-IRS1 region (the MCMV US22 family 
7 
homolog m143), and the UL36-38 region (M36, m38.5) (Rawlinson et al., 1996). The 
important regulatory gene (UL69) of HCMV also has an MCMV homolog (M69), and is 
involved in the transactivation of early genes (Rawlinson et al., 1996). 
Conserved herpesvirus structural genes are also found in both HCMV and MCMV, 
including genes encoding the major capsid protein (UL86/M86), large tegument protein 
(UL48/M48), and the minor capsid protein (UL46/M46) (Rawlinson et al., 1996). Both HCMV 
and MCMV contain homologous genes encoding structural proteins found only in beta-
herpesviruses. These include genes encoding the upper and lower matrix proteins, UL82/M82 
and UL84/M84, respectively, phosphoproteins (UL32/M32 and UL99/M99), and proteins 
involved in virion assembly (UL80 /M80 and UL56/M56) (Rawlinson et al., 1996). 
Genes encoding proteins responsible for nucleotide metabolism, replication and repair 
are also present in HCMV and MCMV. Examples include the uracil-DNA glycosylase 
UL114/M114, ribonucleotide reductase UL45/M45, dUTPase UL72/M72, phosphotransferase 
UL97/M97, and pyruvoyl decarboxylase UL77/M77 (Chee et al., 1990; Rawlinson et al., 
1996). Several conserved genes encoding glycoproteins in herpesviruses have homologs in 
HCMV and MCMV, including gB (UL55/M55), gH (UL75/M75), gM (UL100/M100), and gL 
(UL115/M115) (Rawlinson et al., 1996). 
MCMV contains 6 gene families, 4 of which are homologous to HCMV gene families 
and 2 of which are unique to MCMV (Rawlinson et al., 1996). There are the m02 (m02-m16 
inclusive) and the m145 (m145, m146, m150-m155, m157, m158, m17) gene families, both of 
which encode membrane glycoproteins (Rawlinson et al., 1996). The US22 gene family has 
members in both HCMV and MCMV (M23, M24, m25.1, m25.2, M36, M43, m128/ie2,  and 
m139-m143 ) as well as other herpesviruses (Rawlinson et al., 1996).  MCMV also contains 
members of the HCMV UL25 and UL82 families (M25/M35 and M82/M83, respectively) 
(Rawlinson et al., 1996). The last gene family present in both MCMV and HCMV contains 
homologs to G-protein-coupled receptors (UL33/M33, US27, US28 and UL78/M78) 
(Rawlinson et al., 1996; Chee et al., 1990). Homologs to the cellular gene encoding the  major 
histocompatibility class I (MHC-1) protein, are present in both HCMV (UL18) and MCMV 
(m144) although the 2 viral genes do not share sequence homology with each other 
(Rawlinson et al., 1996). 
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1.2.3  Viral Life Cycle 
The first stage in the viral life cycle is the attachment and penetration of the virus into 
host cells. This is followed by the uncoating of the viral capsid in the cytoplasm, and the 
translocation of the viral genome to the nucleus where DNA replication takes place.  
Subsequently, viral capsids are assembled, and an envelope is acquired as the encapsidated 
virus is transported across the nuclear membrane. De-envelopment occurs in the cytoplasm, 
where additional tegument proteins are incorporated, and the final envelopment of the virion 
takes place. The mature virion is released from the host cell and proceeds to infect other 
susceptible cells. 
Research in both HCMV and MCMV has contributed to the pool of knowledge about 
the CMV life cycle, and many of the important genes involved in the virus life cycle have 
HCMV and MCMV homologs. Even though the descriptions in the following sections are 
mostly derived from research on HCMV, we have listed the MCMV homologs along with the 
relevant HCMV genes, with the assumption that the MCMV genes may have similar functions. 
1.2.3.1  Viral Entry 
In order for viral replication to occur, the virus first needs to be able to attach to and 
enter a susceptible host cell. In herpesviruses, several conserved glycoproteins (gB, gH, gL, 
gM and gN) are known to be involved in this process. Homologs for all of these proteins have 
been identified in HCMV, and are part of three glycoprotein complexes known as gcI 
(gpUL55/gB), gcII (gpUL100/gM and gpUL73/gN) and gcIII (gpUL75/gH-gpUL115/gL-
gpUL74/gO) (Gretch et al., 1988a; Gretch et al., 1988b; Kari and Gehrz, 1992; Kaye et al., 
1992; Kari et al., 1994; Huber and Compton, 1998; Mach et al., 2000). In addition, homologs 
have been identified and characterized in MCMV (Loh et al., 1988; Loh and Qualtiere, 1988; 
Loh, 1991; Rapp et al., 1992; Xu et al.,  1992; Xu et al., 1994; Li et al., 1995; Scalzo et al., 
1995a; Scalzo et al., 2004). 
The first step in viral entry is attachment of the virus to receptors on the host cell, 
mediated by glycoproteins in the viral envelope.  For HCMV, heparan sulfate, integrins, and 
epidermal growth factor receptor have been identified as cell surface receptors (Kari and 
Gehrz, 1992; Compton et al., 1993; Wang et al., 1995; Wang et al., 2003; Feire et al., 2004). 
The binding of HCMV gcII to heparan sulfate proteoglycans on the cell surface is a critical 
step of viral infection (Kari and Gehrz, 1992). The glycoproteins in this complex, gM and gN, 
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interact both covalently, through disulfide bonds, as well as non-covalently (Mach et al., 2000; 
Mach et al., 2005). The covalent interaction is not required for viral replication or the transport 
of the complex out of the endoplasmic reticulum (Mach et al., 2005). Glycoprotein N 
undergoes significant modifications that increase its size from 18 kDa to 50 or 60 kDa in the 
presence of gM (Mach et al., 2000). The MCMV gM homolog has a 47% amino acid identity 
with HCMV gM (Li et al., 1995; Scalzo et al., 1995a), and the MCMV gN homolog (M73) has 
recently been identified (Scalzo et al., 2004). Human CMV is unable to bind to cells lacking 
cell surface heparin sulfate or during competition with soluble heparin (Compton et al., 1993). 
While gB is able to bind to heparin through a site in the carboxy terminal region, it is able to 
remain associated with the surfaces of cells deficient in heparan sulfate proteoglycans 
(Compton et al., 1993; Carlson et al., 1997; Boyle and Compton, 1998). It was also 
determined that pre-treatment of cells with gB significantly affected the ability of HCMV to 
bind to these cells, perhaps due to the lack of availability of appropriate receptors (Boyle and 
Compton, 1998). It appears that the binding of HCMV to heparin sulfate proteoglycans is only 
required at the initial stages of viral attachment to cells, and other receptors are required at 
later steps of virus entry (Boyle and Compton, 1998). One potential candidate for this receptor 
may be cellular integrins (Feire et al., 2004; Wang et al., 2005). 
In both HCMV and MCMV, the gB glycoprotein forms disulfide-linked complexes, is 
expressed late in infection, and is a major constituent of the viral envelope (Loh et al., 1988; 
Loh, 1991; Rapp et al., 1992; Navarro et al., 1993). Although gB genes from all herpesviruses 
share a great deal of conservation, those from MCMV and HCMV are the most similar. The 
gB glycoproteins from both viruses retain the conserved tertiary structures found in all 
herpesviruses and share 45% of their amino acid sequences (Rapp et al., 1992). In addition, the 
beta-herpesviruses share 86.5% amino acid identity in the disintegrin-like domain of gB (Feire 
et al., 2004). Murine CMV has been shown to interact with ?1 integrins, whereas HCMV can 
interact with ?1 and ?3 integrins (Feire et al., 2004). In particular, gH can interact with 
integrin ?v?3 (Wang et al., 2005). 
The epidermal growth factor receptor has also been implicated as an additional cellular 
receptor for HCMV gB (Wang et al., 2003), and has been shown to interact with integrin ?v?3 
during virus entry and signalling (Wang et al., 2005). However, recent data indicated that the 
epidermal growth factor receptor might not play an important role in HCMV entry or 
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downstream signalling (Isaacson et al., 2007). It remains unknown whether there is an 
additional receptor capable of interacting with integrins during HCMV entry into cells. 
Following attachment of virus to host cells through specific receptors, fusion with the 
cell membrane occurs, a process that depends on the gB and gH/gL glycoproteins in other 
herpesviruses (Kinzler and Compton, 2005). A 92.5 kDa protein on the cell surface interacts 
with the gH glycoprotein of HCMV, and may play a role in fusion.  However, the identity of 
this receptor is not yet known (Keay et al., 1989; Keay and Baldwin, 1991). Furthermore, 
early studies indicated that gB and gH/gL were required for cell-cell fusion rather than initial 
attachment of CMV to cells (Keay and Baldwin, 1991; Navarro et al., 1993). The MCMV 
homologs to gH and gL have been identified and show great similarity to their HCMV 
counterparts as well as other beta- and gamma-herpesviruses (Loh and Qualtiere, 1988; Xu et 
al., 1992; Rapp et al., 1994; Xu et al., 1994). 
In HCMV, the gH/gL complex also includes gO, resulting in a heterotrimeric complex 
(Huber and Compton, 1998), or pUL131-128 (Ryckman et al., 2008). If the gO gene is 
deleted, viral growth is attenuated but not prevented as in the case of gH/gL deletion (Hobum 
et al., 2000). The heterotrimeric complex is formed in two steps. The first step involves the 
association of gH and gL (Huber and Compton, 1999) and the second step involves the 
association of gO with the gH-gL complex to form the precursor gCIII complex in the 
endoplasmic reticulum. This complex is then processed to the mature gCIII complex in a post-
endoplasmic reticulum compartment (Huber and Compton, 1999). 
As expected, if the gB, gH, gL and gO glycoproteins of HCMV were expressed 
individually in cells, cell fusion did not occur. However, co-expression of gH and gL enabled 
cell fusion in certain cell lines and the process was inhibited by neutralizing antibodies against 
these glycoproteins (Kinzler and Compton, 2005). Expression of gB and/or gO along with 
gH/gL did not increase the extent of cell fusion (Kinzler and Compton, 2005). Interestingly, if 
gH/gL was co-transfected into cells infected with a strain of HCMV that caused fusion 
regardless of viral infection, cell fusion was enhanced (Milne et al., 1998). 
It appeared that HCMV might use the gH/gL/pUL128-131 complex to enter epithelial 
and endothelial cells by endocytosis and fusion (Wang and Shenk, 2005; Ryckman et al., 
2006) whereas entry into fibroblasts involved the gH/gL/gO complex that mediated fusion 
with the plasma membrane (Wang and Shenk, 2005; Ryckman et al., 2008). Each of the 
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pUL128-pUL131 proteins was able to bind to the gH/gL complex on their own, and in so 
doing either enhanced or inhibited further binding by the other proteins (Ryckman et al., 
2008). Export of gH/gL from the endoplasmic reticulum into the golgi apparatus was greatly 
enhanced with pUL128-pUL131 regardless of the presence of gO (Ryckman et al., 2008). In 
addition, there is evidence to suggest that the formation of a gB/gH complex during viral entry 
is dependent on pUL131-pUL128. Thus these proteins are important mediators of CMV fusion 
(Patrone et al., 2007). 
1.2.3.2  Pre-replication events 
Following fusion of the viral envelope with the cellular membrane, the viral and its 
associated tegument proteins are released into the cytoplasm. The virion is uncoated and viral 
DNA is transported into the nucleus where viral DNA replication will take place. Although not 
a lot of detail is known about this stage of the viral life cycle in CMVs, tegument proteins 
encoded by UL48/M48, UL47/M47, UL49/M49 as well as the major capsid protein encoded by 
UL86/M86 formed a complex that might play a role (Rawlinson et al., 1996; Bechtel and 
Shenk, 2002). UL48/M48 is highly conserved in herpesviruses, and is homologous to HSV-1 
UL36, which encodes a virion structural protein that plays a role in the release of viral DNA 
from capsids (Batterson et al., 1983; Bradshaw et al., 1994). In addition, UL47 was shown by 
Bechtel and Shenk (2002) to have a role in the viral life cycle between viral entry and 
immediate-early gene expression, which was delayed in UL47 mutants. 
Following delivery of the viral genome to the nucleus and before viral DNA replication 
can occur, the virus must suppress the apoptotic response initiated by the host cell. A number 
of viral genes are involved in the prevention of apoptosis at very early times after CMV 
infection, facilitating viral DNA replication by minimizing the effect of host anti-viral 
defences. This is discussed in more detail in section 1.2.4.1. 
During HCMV infection of permissive cells, the host cell cycle is blocked at various 
stages, and particularly during G1-S, and G2-M transitions (Wiebusch and Hagemeier, 1999). 
There is some controversy over when the cell cycle is arrested during virus infection.  
However, it is known that cell cycle arrest mediated by immediate-early 2 (ie2) is crucial for 
efficient viral replication (Petrik et al., 2006). One study demonstrated that ie2 induced cell 
cycle arrest at the G1 stage within 24 hours after infection (Wiebusch and Hagemeier, 1999). 
However, a subsequent study indicated that ie2 induced a shift into the S phase of the cell 
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cycle during viral infection, and blocked cell cycle progression at this point (Murphy et al., 
2000). The ability of ie2 to activate cyclin E was necessary for shuttling cells into the S phase 
(Wiebusch et al., 2003). In cells lacking p53, immediate-early 1 (ie1) blocked the cell cycle at 
the G1/S transition, whereas ie2 blocked the cell cycle at the G2/M checkpoint, allowing 
cellular DNA synthesis but preventing cell division (Castillo et al., 2000; Song and Stinski, 
2005). 
The host cell also has intrinsic defences in place that help protect against CMV 
infection. Cellular proteins involved in these processes include the promyelocytic leukemia 
protein (PML), death-associated protein 6 (Daxx) and histone deacetylases (HDACs) (Tang 
and Maul, 2003; Cantrell and Bresnahan, 2006; Preston and Nicholl, 2006; Saffert and Kalejta, 
2006; Tavalai et al., 2006). These proteins have been shown to act independently and have an 
additive effect on the repression of immediate early gene expression (Tavalai et al., 2008). The 
HCMV tegument protein pp71, encoded by UL82, interacted with and mediated the 
degradation of hDaxx, preventing it from repressing major immediate-early promoter/enhancer 
(MIEP) activity and viral replication (Cantrell and Bresnahan, 2006; Preston and Nicholl, 
2006; Saffert and Kalejta, 2006). In this way, pp71 has the crucial role of activating the MIEP 
to allow efficient viral replication to occur (Liu and Stinski, 1992). Murine homologs of UL82 
have been identified as M82 and M83 (a UL82/UL83 homolog) (Cranmer et al., 1996). The 
mIE1, HCMV IE1 and IE2 proteins were all able to deacetylate HDACs, thus inhibiting their 
repressive activities (Tang and Maul, 2003; Nevels et al., 2004b; Park et al., 2007). 
The promyelocytic leukemia protein, hDaxx, Sp100, the Bloom (BLM) helicase, and 
SUMO-1 (small ubiquitin-like modifier-1) are constituents of the promyelocytic oncogenic 
domains (PODs), also known as nuclear domain 10 (ND10). Many viruses, including 
papovaviruses, polyomaviruses, and members of all subfamilies of herpesviridae have proteins 
that co-localize with PML nuclear bodies (Everett, 2006). During HCMV infection, pp71 
localized to ND10, where it interacted with hDaxx, and facilitated efficient viral DNA 
replication (Ishov et al., 2002). Available evidence suggests that MCMV mIE1 is initially 
targeted to ND10 by either PML or Daxx, and subsequently helps to recruit HDAC-2 (Tang 
and Maul, 2003). Ahn and Hayward (1997) observed that both IE1 and IE2 were present in 
ND10 less than 2 hours post-infection, where the IE1 protein was visualized by 
immunoflourescence as a mixture of diffuse and punctate nuclear patterns. By 4-6 hours post-
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infection the IE1 pattern became exclusively diffuse, indicating that IE1 was able to disperse 
PML, thereby allowing the virus to initiate productive infection more efficiently (Ahn and 
Hayward, 2000). In contrast, the IE2 protein remained distributed in a punctate pattern even up 
to 12 hours post-infection (Ahn and Hayward, 1997). 
The modification of PML by SUMO-1 is required for recruitment of Daxx into PODs 
and its own punctate nuclear localization pattern (Ishov et al., 1999). During HCMV infection, 
IE1 was able to desumoylate PML, preventing it from performing its organizational role 
within ND10, resulting in the dispersion of ND10 proteins (Ahn et al., 1998; Muller and 
Dejean, 1999; Lee et al., 2004). This in turn prevented PML from functioning as a 
transcriptional repressor (Xu et al., 2001). Thus it is not surprising that a MCMV mie1 
deletion mutant had decreased ability to disrupt PML bodies in mouse fibroblasts early after 
infection (Ghazal et al., 2005). It is generally thought that during an infection at high MOI 
(multiplicity of infection), other immediate-early or viral proteins are able to compensate for 
the IE1 defect, modifying PML bodies to some extent so that productive HCMV infection can 
occur (Gawn and Greaves, 2002). When HDAC-2 activity was inhibited with Trichostatin A, 
there was an increase in the amount of mIE1 and M112-113 (also known as E1) proteins 
produced, with 50% more cells expressing E1 (Tang and Maul, 2003). The authors suggested 
that two different processes might occur depending on the MOI of the infection. At low MOI, 
the cell might be able to segregate mIE1 into ND10, resulting in decreased viral activity. With 
a high MOI, there is abundant production of mIE1, resulting in the sequestering of repressive 
cellular proteins via interactions with mIE1 (Tang and Maul, 2003). 
HCMV IE1 and IE2 proteins were shown to interact with SUMO-1 and undergo 
sumoylation (Ahn et al., 2001; Spengler et al., 2002), a process that increased viral replication 
as well as expression of the IE2 protein, but was not required for interaction with PML (Xu et  
al., 2001; Nevels et al., 2004a). During HCMV infection, the expression of PML enhanced the 
rate of IE1 sumoylation (Xu et al., 2001). There are differing reports regarding whether 
sumoylation of IE1 is required for its intracellular localization although it appeared that 
SUMO-1 did not target IE1 to ND10 (Xu et al., 2001; Spengler et al., 2002, Sadanari et al., 
2005). In a similar fashion, SUMO-1 modification was not required for the targeting of IE2 to 
ND10. However, it enhanced IE2 transactivation (Ahn et al., 2001). 
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Once CMV is able to circumvent the cellular defences against viral infection, the 
HCMV IE1 and IE2 proteins and their MCMV homologs, mIE1 and mIE3, have crucial roles 
as transcriptional regulators. The HCMV ie2, and its homologous MCMV mie3 genes are 
essential for viral replication and the initiation of productive infection (Angulo et al., 2000; 
Marchini et al., 2002). The IE2 protein is known as the major transactivator of gene expression 
and is able to activate a wide range of viral and cellular promoters (Pizzorno et al., 1988; 
Stenberg et al., 1990). In contrast, IE1/mIE1 is only required for viral replication in 
human/mouse cells at low MOI, but not at high MOI (Mocarski et al., 1996; Messerle et al., 
1997; Greaves and Mocarski, 1998). Although another mie1 mutant described by Ghazal et al. 
(2005) did not show any impairment in either early gene expression or ability to replicate in 
different cell lines at either high or low MOI, the discrepancy might be attributed to 
differences in the construction of the mutant viruses. 
HCMV IE1 appears to have a role in transactivating delayed early (DE) genes (Gawn 
and Greaves, 2002). For instance, when IE1 was deleted, the accumulation of ppUL44 (the 
DNA polymerase processivity factor, a DE protein) during low MOI infection was delayed, 
and DNA replication compartments were not established (Greaves and Mocarski, 1998). In 
contrast, there is normal accumulation of IE2 and ppUL112-113 proteins in cells infected with 
ie1 deletion mutants at low MOI, indicating that these proteins are not as strongly dependent 
on IE1 expression as ppUL44 (Gawn and Greaves, 2002). These experiments have also been 
performed in semi-permissive cells with similar results, where the expression of certain late 
proteins such as ppUL99 might even be delayed at high MOI (Ahn and Hayward, 2000). The 
IE2 protein may also be able to direct DE gene transcription as the amount of IE2 present at 
PML bodies increased during infection with IE1-negative viruses (Ahn and Hayward, 2000). 
These growth properties are similar to those observed during MCMV infection of non-murine 
cell lines (unpublished results in our laboratory). 
 The IE1 protein was shown to positively autoregulate the transcription of the HCMV 
MIEP through an NF?B site in the enhancer  (Stenberg and Stinski, 1985; Cherrington and 
Mocarski, 1989). In this way, IE1 is able to augment IE2 activation of early and late viral 
genes (Malone et al., 1990; Stenberg et al., 1990). In addition, the IE2 protein was able to 
repress the MIEP by directly binding to the cis-repression signal (Stenberg et al., 1990; Lang 
and Stamminger, 1993). In addition to IE1 and IE2, viral accessory transactivators such as 
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TRS1/IRS1, UL36-UL38, and UL112-UL113 were also necessary for activation of DE 
promoters (Stasiak and Mocarski, 1992; Pari and Anders, 1993; Iskenderian et al., 1996). In 
addition, when co-transfected with genes encoding IE1 and IE2, IRS1 and TRS1 enhanced the 
activity of a late promoter (Stasiak and Mocarski, 1992). Further studies showed that these 
proteins were able to up-regulate the activity of promoters only in the presence of IE1 and IE2 
(Romanowski and Shenk, 1997). These proteins also up-regulated the activity of immediate-
early promoters with the help of pUL69, a tegument protein present in virions (Romanowski et 
al., 1997). Similarly, IE2 interacted with components of the basal transcription machinery, 
such as the TATA binding protein, resulting in the activation of several promoters (Caswell et 
al., 1993). In addition, both HCMV IE1 and IE2 were able to interact with specific 
transcription factors and nuclear proteins such as c-Jun, SP-1, E2F1, Cardiotrophin 1, the 
hTAFII130 component of TFIID, p107, and PML (Lukac et al., 1994; Hayhurst et al., 1995; 
Margolis et al., 1995; Scully et al., 1995; Poma et al., 1996; Lukac et al., 1997; Ahn et al., 
1998). 
Initiation of the formation of HCMV DNA replication compartments occurred in 
structures that bud from PODs and then progressed into larger nuclear compartments that were 
clearly visible in infected cells (Ahn et al., 1999). The HCMV UL112/113 or MCMV 
M112/113 genes encode four phosphoproteins (pp34, pp43, pp50 and pp84 in HCMV) that co-
localize with viral DNA prior to viral DNA replication and play a crucial role in the initial 
steps of replication compartment formation (Iwayama et al., 1994; Yamamoto et al., 1998; 
Ciocco-Schmitt et al., 2002). When all 4 proteins were expressed, they localized to PODs, and 
the pp84 protein in particular was required for the targeting of the other 3 proteins (Park et al., 
2006). In addition, pUL84, which contained a nuclear localization signal (Xu et al., 2002), was 
essential for the formation of replication compartments (Sarisky and Hayward, 1996). The pre-
replication compartments contained several other viral proteins, including IE2 (but not IE1) 
and the essential replication proteins ppUL44 and pUL57 (Penfold and Mocarski, 1997; Ahn 
et al., 1999; Xu et al., 2002). In particular, the localization of ppUL44 to these compartments 
required the presence of all four ppUL112/113 proteins as well as pUL84 (Xu et al., 2004; 
Park et al., 2006). However, the localization of IE2 to replication compartments appeared to be 
more complex. Both pUL84 and an interaction between IE2 and viral DNA have been 
suggested to be responsible for its recruitment into ND10 (Xu et al., 2004; Sourvinos et al., 
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2007). In addition, MCMV ppM112-113 proteins have been demonstrated to interact with 
mIE3 (the MCMV homolog of HCMV IE2) in a complex with PML, thereby sequestering 
mIE3 into replication compartments and preventing the negative regulation of the major 
immediate early promoter (Tang et al., 2005). 
1.2.3.3  Viral DNA Replication 
A set of 11 viral genes is required for the initiation of DNA replication from oriLyt, the 
origin of DNA replication during lytic infection in CMV. This included 6 core herpesvirus 
genes which are homologous to the essential HSV-1 replication genes: a DNA polymerase 
(UL54/M54), a polymerase processivity factor (UL44/M44), a single stranded DNA-binding 
factor (UL57/M57), and the helicase-primase complex consisting of a primase-helicase 
(UL70/M70), a helicase (UL105/M105) and a primase-associated factor (UL102/M102) (Pari 
and Anders, 1993; Pari et al., 1993; Loh et al., 1994; Rawlinson et al., 1996; McMahon and 
Anders, 2002). In addition, 5 other genes that show no obvious homology to genes in alpha- or 
gamma-herpesviruses are required to complement oriLyt-dependent DNA replication: 
UL84/M84, UL112-UL113/M112-M113, and the regulatory genes UL36-38 (M36, m38.5), ie1-
ie2 (mie1-mie3), and TRS1/IRS1 (m143) (Pari and Anders, 1993; Pari et al., 1993; Rawlinson 
et al., 1996). 
Thus far only one oriLyt has been identified in both MCMV and HCMV. It is located 
upstream (5’) of the UL57/M57 genes for both viruses (Hamzeh et al., 1990; Anders and 
Punturieri, 1991; Masse et al., 1997), and shows little sequence homology to the origins of 
replication in alpha-herpesviruses (Hamzeh et al., 1990). The MCMV and HCMV oriLyt 
contain several duplicated and inverted sequences, as well as core regions of 1.7 kb and 1.5 kb, 
respectively (Hamzeh et al., 1990; Anders and Punturieri, 1991; Masse et al., 1992; Masse et 
al., 1997). In HCMV and MCMV, oriLyt activity also requires sequences flanking the core 
region, and sequences in the left flanking region in particular (Anders et al., 1992; Masse et 
al., 1997; Borst and Messerle, 2005). These flanking regions contain binding sites for 
transcription factors which could function as promoter sequences (Hamzeh et al., 1990; 
Anders et al., 1992; Masse et al., 1997; Borst and Messerle, 2005). One of these promoters lies 
between UL57 and oriLyt and was shown to be responsible for regulating UL57 expression 
and activating oriLyt (Kiehl et al., 2003). The smallest replicator transcript (SRT) RNA, which 
might be involved in regulation of lytic DNA replication, was transcribed from HCMV oriLyt 
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(Huang et al., 1996), which also contained sites for two virus-associated RNAs (vRNA-1 and 
vRNA-2) that formed RNA-DNA hybrid structures during or after DNA replication (Prichard 
et al., 1998). 
The initiator of HCMV DNA replication, pUL84, bound to oriLyt specifically through 
a stem-loop region within this RNA/DNA hybrid structure (Colleti et al., 2007), and was 
absolutely required for viral DNA replication to occur, but not for the expression of viral genes 
(Xu et al., 2004). It contains a nuclear targeting domain that includes two leucine-rich nuclear 
export signals, enabling the shuttling of proteins between the nucleus and the cytoplasm 
(Lischka et al., 2006).  This suggested that pUL84 might have an as yet undefined role in the 
cytoplasm (Lischka et al., 2006). The pUL84 protein interacted with many cellular proteins, 
including casein kinase II, p32, ubiquitin-conjugating enzyme E2, and annexin A2 (Gao et al., 
2008). It could interact with other pUL84 molecules through an oligomerization domain, as 
well as viral proteins such as pp65, a component of the capsid, and IE2 (through a leucine 
zipper domain) (Colletti et al., 2004; Gao et al., 2008;). Both the pUL84-pUL84 and the 
pUL84-IE2 interactions appeared to be required for DNA replication (Colletti et al., 2004). 
Interestingly, pUL84 was able to inhibit transactivation of viral gene expression by IE2, and 
enhanced the negative autoregulation of the MIEP by this gene (Gebert et al., 1997). The 
pUL84 protein also interacted with ppUL44, implying a potential role for the polymerase 
accessory protein in the initiation of DNA synthesis (Gao et al., 2008). 
Other protein-protein interactions were shown to be important for viral DNA 
replication. For example, interaction between pUL54 and ppUL44 resulted in increased 
processivity of the DNA polymerase (Ertl and Powell, 1992; Weiland et al., 1994). A region of 
pUL54 distinct from the ppUL44-binding domain contained two nuclear localization signals, 
although only one is required for nuclear localization (Alvisi et al., 2006). The accessory 
proteins UL36-38, ppUL112-113, IRS1, and IE1/IE2 cooperated with each other to regulate 
the expression of the 6 core proteins required for lytic DNA replication (Stasiak and Mocarski, 
1992; Iskenderian et al., 1996). In addition, ppUL112-113 expression is regulated by IRS1 and 
UL36-38 (Iskenderian et al., 1996). The MIE proteins had the strongest affect on core protein 
expression, followed by UL36-38 (Iskenderian et al., 1996). The IR1 (inverted repeat-1) 
sequence in the UL54 promoter was required for its regulation by MIE proteins and ppUL112-
113 proteins at early times of infection (Kerry et al., 1996). In particular, the IE2 protein 
18 
bound to IR1 in a complex with the cellular transcription factor SP1 (Luu and Flores, 1997; 
Wu et al., 1998). However, at late times of infection, the UL54 promoter was regulated by the 
activating transcription factor-1 (Kerry et al., 1997). 
1.2.3.4 Virus Assembly and Egress 
Following viral DNA replication, CMV genomes were arranged in head-to-tail 
concatemers that needed to be cleaved into genome-size lengths prior to packaging into 
capsids. The large subunit of the terminase, encoded by UL56/M56, was responsible for 
binding to the pac sites on the viral genome (Bogner et al., 1998) while cleavage at these sites 
was carried out by the small subunit of the terminase encoded by UL89/M89 (Scheffczik et al., 
2002). The two terminase subunits interacted with each other and localized to viral replication 
centers, suggesting a potential association between the DNA replication and packaging 
processes (Hwang and Bogner, 2002; Thoma et al., 2006). Once the viral DNA genome was 
cleaved, it was translocated into capsids through a portal formed by pUL104 via interactions 
with the large terminase subunit (Dittmer et al., 2005). This process was also dependent on 
pUL56 ATPase activity (Hwang and Bogner, 2002). More recently, pUL52/pM52 was shown 
to play a role in both the cleavage and packaging of viral DNA (Borst et al., 2007). The unique 
subnuclear location of pUL52, which appeared to enclose compartments where DNA 
replication and packaging took place, suggested that it might provide a link between the two 
processes (Borst et al., 2007). 
Once capsids were assembled, they underwent maturation and egress from the nucleus, 
processes believed to be mediated by highly conserved components of the nuclear egress 
complex (pUL53/pM53 and pUL50/pM50). In addition, pUL32/pM32 might also be required 
as either a stabilization factor during capsid assembly or during nuclear egress (Meyer et al., 
1997; AuCoin et al., 2006). It is generally thought that CMV virions undergo a primary 
envelopment, followed by a de-envelopment and then a secondary envelopment.  Prior to 
primary envelopment, viral structural proteins (pUL83, pUL69 tegument proteins, and pUL86 
and pUL49/49 capsid proteins) accumulated in the nuclear matrix, which was tightly 
associated with the inner nuclear membrane (Sanchez et al., 1998). The proteins of the nuclear 
egress complex played a major role in the primary envelopment of CMV capsids by 
designating the site on the nuclear lamina where viral capsid egress could occur (Muranyi et 
al., 2002). The M50 protein was responsible for the penetration of capsids through the nuclear 
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envelope, a process that required the dissolution of the nuclear lamina through the action of 
protein kinase C (Muranyi et al., 2002). A proline rich region in both pM50 and its HCMV 
homolog pUL50 was required for nuclear egress of capsids containing viral DNA (Rupp et al., 
2007). 
Two of the most abundant tegument proteins, pUL99 and pUL32, as well as 
glycoprotein B (UL55) were not found to be associated with the nuclear matrix (Sanchez et al., 
1998). These proteins, along with pUL53, ppUL83 (pp65), gH and gp65 appeared to 
accumulate in a cytoplasmic assembly compartment where additional proteins might be 
incorporated into virus particles following their egress from the nucleus and de-envelopment 
in the cytoplasm (Sanchez et al., 2000a; Dal Monte et al., 2002; Silva et al., 2003). When 
pUL99 was transfected alone into cells, it localized to the endoplasmic reticulum-golgi 
intermediate compartment, suggesting that other viral proteins were required for its 
translocation to the assembly compartments in the cytoplasm (Sanchez et al., 2000a; Sanchez 
et al., 2000b). The pUL26 tegument protein had a role in regulating the phosphorylation status 
of the pUL99 and pUL83 tegument proteins and maintaining their stability (Munger et al., 
2006). This stability is crucial, as pUL99/pM99 appeared to be involved in the final 
envelopment of CMV in the cytoplasm (Silva et al., 2003). Mutations in this protein resulted 
in the accumulation of non-enveloped capsids in the cytoplasm in spite of normal expression 
of late proteins (Silva et al., 2003). 
The proteins present in both the MCMV and HCMV virions have been identified 
(Kattenhorn et al., 2004; Varnum et al., 2004).  In HCMV, 71 virally encoded proteins and 70 
cellular proteins were found to be associated with virions (Varnum et al., 2004). The most 
prevalent viral glycoprotein and protein were gM and pUL83, respectively (Varnum et al., 
2004). In MCMV, 7 cellular proteins and 58 virally encoded proteins were found to be 
associated with virions, including capsid, tegument, regulatory, and replication proteins, as 
well as glycoproteins (Kattenhorn et al., 2004). Annexin II represented a cellular protein that 
was associated with both HCMV and MCMV virions and was known to interact with gB 
(Pietropaolo and Compton, 1997; Kattenhorn et al., 2004; Varnum et al., 2004;). Since this 
interaction was non-essential for viral entry into cells, it had been suggested that it might be 
required for the acquisition of primary and final envelopes during virion production 
(Pietropaolo and Compton, 1999). 
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1.2.4  Viral-host interactions 
The interactions between virus and host cell often dictate whether an infection will be 
successful.  The nature of these interactions can be affected by the types of cells and tissues 
infected by the virus, or the species of the infected host. Since HCMV and other CMVs are 
able to enter cells and express a subset of viral genes in non-permissive hosts, the block to 
viral replication is likely at a point in the viral life cycle after entry (Mocarski et al., 2007). 
1.2.4.1 Host and tissue specificity 
A characteristic trait of CMVs is their host species specificity, which means that they 
usually only undergo productive infection in their natural host. This is quite different from the 
alpha-herpesviruses, including HSV-1, which have a broad host range. However, even 
amongst CMVs there are differences in the degree of species specificity. For instance, HCMV 
is known to have very strict species specificity and is only able to undergo productive infection 
in human diploid fibroblasts (Lafemina and Hayward, 1988). In contrast, MCMV is noted to 
have the ability to productively infect many cell lines, including those derived from other 
species, albeit only at high MOI (Kim and Carp, 1971; unpublished data from our laboratory). 
Murine CMV was able to absorb to and cause cytopathic effects (CPE) in human diploid cells 
and complete a portion of the replicative cycle even though productive infection did not occur 
(Kim and Carp, 1972). The ability of MCMV to cause typical CPE in infected human cells 
was not dependent on viral DNA synthesis (Kim and Carp, 1972). Similar observations were 
made during HCMV infection of guinea pig cells (Fioretti et al., 1973). Interestingly, while 
MCMV was able to infect rat cells, RCMV was unable to infect murine or human cells and 
productive infection was limited to rat embryo fibroblasts (Bruggeman et al., 1982). 
There are distinct differences in the permissiveness of human, monkey, and murine 
cells for HCMV, SCMV and MCMV (Lafemina and Hayward, 1988). Murine CMV and 
SCMV were shown to have a much broader host range than HCMV. Although infection of 
different types of diploid fibroblasts results in IE gene expression for all three viruses, only 
MCMV progresses to the viral DNA replication stage in each cell type (Lafemina and 
Hayward, 1988). Productive MCMV infection can occur in human cells if HCMV IE1 and 
tegument proteins are provided (Tang and Maul, 2006). These proteins have important 
functions required for effective cross-species infection, including interactions of the tegument 
protein pp71 with the Daxx repressor, repression of the interferon response by pp65 and 
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inhibition of Daxx and HDAC by IE1 (Tang and Maul, 2006). In contrast, SCMV DNA 
replication was observed in monkey and human cells, whereas HCMV DNA replication only 
occurred in human cells (Lafemina and Hayward, 1988). By comparison, SCMV was able to 
express IE genes in a wider range of cells, and HCMV was the most restricted (Lafemina and 
Hayward, 1988).  Interestingly, HCMV is able to progress to the viral DNA replication stage 
of the life cycle in primary chimpanzee skin fibroblasts but not transformed chimpanzee 
fibroblasts, illustrating the close lineage between the human and chimpanzee species (Perot et 
al., 1992). 
A study by Jurak and Brune (2006) highlighted the importance of apoptosis during the 
infection of human cells by MCMV. Although MCMV was able to infect and replicate in 
human embryonic kidney cells, the release of virus was delayed. In addition, when these cells 
were infected with MCMV at low MOI, virus production and cell-cell spread was lower than 
in permissive cells (Jurak and Brune, 2006). It was determined that MCMV infection of non-
permissive human cells caused apoptosis, a process that was likely prevented during 
permissive infection. As the authors noted, human cell lines permissive for MCMV infection 
contain the adenoviral genes E1A, which is pro-apoptotic, and E1B, which is anti-apoptotic 
(Jurak and Brune, 2006). Interestingly, when non-permissive human cells were transfected 
with vectors expressing the E1B-19k gene, apoptosis induced by MCMV was prevented, and 
productive infection occurred. Thus the barrier to cross-species infections appeared to be the 
induction of apoptosis in non-permissive cells (Jurak and Brune, 2006). However, even when 
the presence of an anti-apoptotic protein facilitated MCMV replication in human cells, the 
progress of infection was still delayed, suggesting that there were other factors involved. 
The first HCMV genes identified as having a role in preventing apoptosis of infected 
cells were ie1 and ie2, which blocked apoptosis induced by either tumor necrosis factor 
(TNF)-?, or superinfection by EIB-19k-deficient adenovirus, but they did not interact with 
either Bcl-2 (B cell lymphoma/leukemia 2) or Bax (Bcl-2-Associated X Protein) (Zhu et al., 
1995). Since these were immediate-early genes, their expression prevented the host cell from 
mounting an early antiviral response (Zhu et al., 1995). The IE1 and IE2 proteins activated the 
phosphatidylinositide 3’-OH kinase, which in turn activated Akt (a cellular kinase), leading to 
the inhibition of apoptosis (Yu and Alwine, 2002). In addition, IE2 was able to interact with 
and repress the transcription of p53, a well-known apoptotic protein, thereby preventing it 
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from activating the apoptosis pathway (Tsai et al., 1996). This interaction is likely critical to 
the success of CMV infection in permissive cells, especially since p53 is stabilized during 
HCMV infection (Muganda et al., 1994). Human CMV was also able to sequester p53 into 
replication centers in infected cells, which might have the dual effect of repressing p53 
apoptotic activity and enhancing HCMV replication at the same time (Fortunato and Spector, 
1998; Casavant et al., 2006). 
Although other herpesviruses contain homologs of Bcl-2 or FLIP (FLICE-like 
inhibitory protein), which are anti-apoptotic proteins, no CMV homologs to these cellular 
proteins are known to exist (Goldmacher et al., 1999). However, as previously mentioned, 
UL37 encodes a viral mitochondrial-localized inhibitor of apoptosis (vMIA) which has a 
similar mechanism of action to Bcl-2. This protein was designated vMIA due to its localization 
to the mitochondria as well as its anti-apoptotic activity (Goldmacher et al., 1999). Murine 
CMV m38.5 is located in the same region of the viral genome as HCMV UL37, and appeared 
to function in the same way as vMIA, by localizing to the mitochondria and inhibiting 
apoptosis induced by proteasome inhibitors. However, it was unable to prevent Fas-mediated 
apoptosis (McCormick et al., 2005), and did not share sequence homology with UL37 
(McCormick et al., 2005). 
Arnoult et al. (2004) demonstrated that vMIA could prevent apoptosis mediated by 
Bax but not Bak (Bcl-2 homologous antagonist/killer). The vMIA protein was able to 
inactivate Bax-mediated membrane permeabilization, whereas Bcl-2 inactivated truncated Bid 
(Bcl-2 interacting protein) mediated activities (Arnoult et al., 2004). In addition, HCMV 
vMIA did not prevent Fas activation of caspase 8 or cleavage of Bid (Goldmacher et al., 
1999). If the cellular bcl-2 or bcl-XL genes, or the HCMV UL37 gene were over-expressed 
during MCMV infection of human cells, or if human cells were infected by recombinant 
MCMV containing HCMV UL37, apoptosis was prevented (Jurak and Brune, 2006). 
Interaction of vMIA with GADD45 (growth arrest and DNA damage 45) was required for its 
anti-apoptotic activity (Smith and Mocarski, 2005). 
Another anti-apoptotic protein of CMV is vICA (viral inhibitor of caspase 8 
activation), the gene product of UL36, which has a distinct mechanism compared to vMIA 
(Skaletskaya et al., 2001).  Although vICA has a similar function to FLIPs, it lacks any 
homology to them, much the same as the case for vMIA and Bcl-2 (Skaletskaya et al., 2001).  
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Cells expressing UL36 were resistant to apoptosis mediated by Fas, TNF-?, TNF-related 
apoptosis-inducing ligand, doxorubicin, and infection with E1B-19k deficient adenovirus. The 
pUL36 protein was able to interact with the pro domain of caspase 8, preventing its activation, 
and thus functioned at an earlier point in the Fas-mediated apoptosis pathway than vMIA 
(Goldmacher et al., 1999; Skaletskaya et al., 2001). The M36 protein of MCMV is 
homologous to HCMV vICA and designated M-vICA. It is part of the US22 family of genes, 
and requires motif IV for its activity, suggesting that one of the roles of the US22 family is to 
mediate anti-apoptotic activities (McCormick et al., 2003). M36 was not required for virus 
growth on endothelial cells, but its anti-apoptotic activity increased the viability of 
macrophages (Ménard et al., 2003). However, unlike HCMV vICA, M-vICA was essential for 
in vivo viral replication (Ménard et al., 2003; Goldmacher, 2005). 
 It was initially thought that UL36 represented a redundant viral function protecting 
against apoptosis since studies leading to this conclusion used a viral strain lacking a 
functional UL36 (Reboredo et al., 2004).  The deletion of UL37 in a viral strain that contained 
a functional UL36 gene did not affect the replication of HCMV or induce caspase 3 dependent 
apoptosis (McCormick et al., 2005). It was suggested that vICA initially prevented apoptosis 
of HCMV infected cells, and vMIA protected against apoptosis induced by proteasome 
inhibitors later on in infection (McCormick et al., 2005).   
The MCMV M45, a homolog of the ribonucleotide reductases, was another anti-
apoptotic protein essential for the growth of MCMV on endothelial cells. However, this gene 
was not required to prevent apoptosis in fibroblasts (Brune et al., 2001). In contrast, the gene 
product of HCMV UL45 did not have an anti-apoptotic function (Hahn et al., 2002). Murine 
CMV m41, which is part of the m41, m40 and m39 gene cluster, localized to the golgi 
apparatus and had an anti-apoptotic function at late stages of infection (Brune et al., 2003).  
Although expression of m41 prevented premature apoptosis in infected cells, it was not 
essential for viral growth (Brune et al., 2003). 
MCMV was able to protect virally infected dendritic cells from apoptosis (Andoniou et 
al., 2004).  During this process, Bim (Bcl-2 interacting mediator of cell death), a Bcl-2 family 
member, was upregulated whereas other Bcl-2 family members did not experience any change 
in expression. The pro-apoptotic protein Bim localized to the mitochondria as a result of 
induction of cellular apoptotic pathways. In addition, the expression of an anti-apoptotic 
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protein Bfl-1/A1 was upregulated during MCMV infection of dendritic cells.  Bax remained 
targeted to and oligomerized at the mitochondria in these infected cells even when growth 
factors were not present, and the mitochondrial membrane potential did not change (Andoniou 
et al., 2004). However, an amino terminal epitope of Bax was not exposed during MCMV 
infection of dendritic cells in the absence of growth factors. This anti-apoptotic function was 
not regulated by M36, m38.5 or M45 (Andoniou et al.,  2004). 
In summary, the host range of CMVs appears to be regulated by several viral and 
cellular factors.  Many of these factors are likely to be involved in evading the host defences.  
For instance, there appears to be a link between productive viral infection and the blocking of 
apoptosis in infected cells.  Viral infection can cause cellular stress, cell cycle arrest, and DNA 
damage, leading to apoptosis.  This host strategy allows infected cells to be eliminated before 
virions can be released to infect other cells in the host system.  Elucidation of the factors 
involved should be beneficial to the development of HCMV vaccines and anti-viral drugs. 
1.2.4.2  Host defences against viral infection 
Upon viral infection, the host organism mounts innate, cell-mediated and humoral 
immune responses. Innate responses involve natural killer and dendritic cells, the action of 
interferons, and the activation of dsRNA activated protein kinases. Cell-mediated responses 
involve recognition of viral proteins by cytotoxic T-lymphocytes (CTLs). Humoral responses 
involve the recognition of viral antigens by the immune system and the production of 
antibodies against these antigens. The virus must be able to circumvent these host defences in 
order to initiate productive infection of the host organism. 
1.2.4.2.1  Innate immune responses 
Natural killer (NK) cells are able to recognize MHC class I molecules on the surface of 
virus infected cells and are critical in the control of MCMV infection.  Cell surface receptors 
such as the Ly49H activation receptor encoded by the Cmv1 resistance locus, a part of the NK 
cell gene complex, are expressed in NK cells (Brown et al., 2001; Daniels et al., 2001; Lee et 
al., 2001a).  During MCMV infection of resistant mouse strains (such as B6), the MHC class-I 
like m157 protein was expressed on the surface of infected cells and bound to the Ly49H 
receptor, causing the induction of NK cell mediated cell death, and secretion of interferon and 
chemokines (Arase et al., 2002; Smith et al., 2002). However, Cmv1-mediated resistance to 
MCMV infection is rare among inbred and outbred (wild) mouse strains (Scalzo et al., 1995b; 
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Scalzo et al., 2005). There are different mechanisms for resisting NK cell mediated cell death, 
depending on the strain of mouse infected with MCMV. For instance, resistance to MCMV 
infection in strains containing the Cmv2 (the NZW strain), Cmv3 (the MA/MY inbred strain), 
or Cmv4 (PWK/Pas strain) loci did not involve interactions between Ly49H and m157.  
Instead, Cmv3 resistance involves the NK cell receptor Ly49P, whereas receptors enabling 
Cmv2 and Cmv4 resistance had not yet been identified (Rodriguez et al., 2004; Desrosiers et 
al., 2005; Adam et al., 2006). 
Murine CMV and HCMV encode genes that are able to help counteract host immune 
responses. There is evidence that m157 can act as a viral immune evasion gene by preventing 
the action of NK cells in susceptible mouse strains (Arase et al., 2002). In addition, MCMV 
infected cells can avoid NK cell mediated cell death by the decoy action of UL18/m144 genes 
which encoded MHC class-I like proteins (Beck et al., 1988; Rawlinson et al., 1996; Farrell et 
al., 1997; Reyburn et al., 1997). Human CMV UL18 binds to the leukocyte immunoglobulin-
like receptor on the cell surface and inhibits the activity of NK cells and other immune cells 
(Cosman et al., 1997). In addition, MCMV m145, m152, and m155 genes encode proteins that 
decrease the possibility that NK cell receptors would detect stress related molecules produced 
as a result of MCMV infection by down-regulating their expression (Hasan et al., 2005; 
Krmpotic et al., 2002; Lodoen et al., 2003; Lodoen et al., 2004; Krmpotic et al., 2005). All 
these genes are highly conserved in MCMV strains isolated outside the laboratory (Smith et 
al., 2006). 
Another target for MCMV during viral infection are dendritic cells, which need to 
interact with NK cells to enable their activation (Andrews et al., 2001). Initially, MCMV 
infection of dendritic cells caused the production of cytokines that in turn help to activate NK 
cells (Andrews et al., 2001; Andoniou et al., 2005). However, later on in infection, the 
infected dendritic cells became non-functional (Andrews et al., 2001; Mathys et al., 2003).  
Interestingly, in resistant mice containing the Cmv1 gene locus, the propagation of NK cells 
expressing Ly49H on the cell surface depended on the presence of CD8?+ dendritic cells 
(Andrews et al., 2003). 
The IRS1 and TRS1 proteins also have a crucial role in the viral evasion of the host 
immune response by preventing the activation of a pathway that would block viral replication 
(Child et al., 2004).  These proteins were able to prevent the inhibition of protein synthesis by 
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the cell, a process involving the phosphorylation of the eukaryotic translation factor eIF-2? 
and the activation of RNase L, resulting in RNA degradation (Child et al., 2004). IRS1 and 
TRS1 could also help the virus evade this dsRNA activated antiviral pathway by binding to 
dsRNA (Cassidy, 2005; Hakki and Geballe, 2005). TRS1 was able to retain protein kinase R in 
the nucleus, preventing its activation and the subsequent induction of the dsRNA antiviral 
pathway (Hakki et al., 2006). TRS1, but not IRS1, is required for the production of infectious 
virus (Blankenship and Shenk, 2002). 
Another important host defence mechanism that must be circumvented by viruses is the 
interferon (IFN) response. Interferons can be divided into two classes. Type I interferons are 
produced in response to viral infection, whereas type II interferons are released by NK cells 
and T cells when they are activated upon recognition of infected cells (Hengel et al., 2005). 
Type I interferons use the IFN-?/? receptors whereas Type II interferons bind to IFN-? 
receptors. Activation of the IFN-?/? receptor results in the induction of IFN-stimulated 
response elements whereas IFN-? receptor signalling activates the gamma activated sequences 
(Hengel et al., 2005). Both of these pathways represent different parts of the Jak-STAT (signal 
transducers and activators of transcription) pathway. Murine CMV was able to circumvent the 
host-mediated type I and type II interferon antiviral defences through M27 (Hengel et al., 
1994; Lucin et al., 1994; Heise et al., 1998; Zimmermann et al., 2005). The M27 protein 
bound to STAT2 and caused its degradation. Thus lack of this gene resulted in susceptibility to 
type I interferon, as well as type II interferon, which required functional type I interferon for 
its activity (Zimmermann et al., 2005). In addition, IE2 could block the IFN-? response while 
IE1 counteracted the type I-IFN response during HCMV infection (Taylor and Bresnahan, 
2005; Paulus et al., 2006). 
1.2.4.2.2 Cell-mediated responses 
Cell-mediated immune responses represent an important host defence mechanism 
against CMV infections. Cytotoxic T-lymphocytes are able to kill virus-infected cells by 
recognizing viral peptides presented by the MHC class-I molecules on the surfaces of these 
cells. In MCMV, the major target of CTLs was mIE1 (Reddehase et al., 1987). Although IE1 
did represent a target, the major target for CTLs in HCMV-infected cells was pp65 (Riddell et 
al., 1991; Wills et al., 1996; Gyulai et al., 2000; Khan et al., 2002). Due to the vast sequence 
diversity in mie1 in wild mice, CTLs specific for mie1 from the K181 and Smith laboratory 
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strains of MCMV did not recognize these variants (Lyons et al., 1996). In contrast, the CTL 
epitopes on pp65 were highly conserved in HCMV strains, and although HCMV IE1 also 
showed significant sequence variation, CTLs were still able to recognize these variants 
(Solache et al., 1999; Prod’homme et al., 2003). The IE1 protein of HCMV was 
phosphorylated by pp65, thus preventing CTLs from recognizing it as a viral target (Gilbert et 
al., 1996). 
Both self and foreign antigens (such as MCMV IE1 and HCMV pp65) are presented to 
CTLs on cell surfaces by MHC class-I molecules. Therefore, viruses target these molecules as 
a way to evade CTL responses to viral infection. The HCMV genes involved in immune 
system evasion through modulating antigen presentation by MHC class-I molecules are US2, 
US3, US6 and US11, all of which encode glycoproteins. US2 and US11 were involved in 
facilitating the destruction of newly synthesized MHC class I molecules by the proteasome in 
the cytosol (Wiertz et al., 1996a, 1996b). The US3 protein prevented the maturation of MHC 
class-I and its translocation from the endoplasmic reticulum during the immediate-early phase 
of infection, a function that might require oligomerization of US3 molecules (Jones et al., 
1996; Misaghi et al., 2004). The US6 protein formed a complex with the transporter of antigen 
processing, thus preventing peptides from being recognized by the immune system by 
retaining MHC class-I molecules in the endoplasmic reticulum (Lehner et al., 1997). Murine 
CMV genes m06, m152 and m04 encoded gp48, gp40, and gp34, respectively. Both m06 and 
m152 were highly conserved amongst MCMV strains, whereas m04 was quite variable (Smith 
et al., 2006). The m152 gene encoded a glycoprotein that prevented CTL recognition of the ie1 
peptide by blocking MHC class-I presentation of this antigen on the cell surface (Del Val et 
al., 1992; Ziegler et al., 1997). In contrast, the m04 gene product did not prevent MHC class-I 
surface expression but was able to regulate the CTL response (Kleijnen et al., 1997; Kavanagh 
et al., 2001).  The m06 gene product bound to MHC class I molecules and targeted them for 
degradation (Bubeck et al., 2002). 
1.2.4.2.3  Humoral responses 
Humoral immune responses produce antibodies against specific viral antigens that can 
neutralize virus infectivity and prevent cells from being infected. Humoral responses initially 
involve the production of IgM antibodies, followed by IgG antibodies, which persist in the 
host. During HCMV infection, gB represented the main target of the humoral response, and it 
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was the target of more than half of the neutralizing antibodies produced by the host (Britt et 
al., 1990). In MCMV, gB represented a target for both neutralizing and non-neutralizing 
antibodies (Loh et al., 1988; Rapp et al., 1992). In addition, several neutralizing antibodies 
were directed against gH during HCMV infection (Urban et al., 1994). Non-neutralizing 
antibodies specific for other HCMV proteins, such as pp150 (encoded by UL32), had also been 
identified (Jahn et al., 1987). 
Human CMV was able to evade humoral immune responses by up-regulating the 
expression of Fc receptors that could bind IgG molecules (MacCormac and Grundy, 1996). 
This could help to prevent virus specific antibodies from interacting with complement and 
inducing antiviral immune responses. Secondly, cytomegaloviruses encoded homologs of the 
Fc receptor, such as the TRL11/IRL11 and UL119/118 proteins in HCMV, and the m138 
protein in MCMV (Thale et al., 1994; Lilley et al., 2001; Atalay et al., 2002). Although the 
MCMV Fc receptor homolog was required for productive infection in normal or 
immunosuppressed mice, it was not required during infection of newborn mice (Crnkovi?-
Mertens et al., 1998). A third way for cytomegaloviruses to evade the humoral immune 
response was through the regulation of complement activation. The infecting virus was able to 
control the expression of cellular regulators of complement activation in infected cells (Spiller 
et al., 1996, 1997). Normally, during viral infection, complement could recognize and attack 
viral particles that had antibody bound to their envelope glycoproteins. Murine CMV infection 
resulted in the upregulation of CD46, which functioned to prevent the complement-mediated 
lysis of virally infected cells (Nomura et al., 2002). 
1.2.5  Pathogenesis 
Cytomegaloviruses infect 40-60% of the population asymptomatically, often with the 
disease remaining undiagnosed. However, the virus can remain in the host in a latent state in 
specific cell types, and cycle between periods of latency and reactivation. In an 
asymptomatically infected host, the virus can still be transmitted upon reactivation. The ability 
of CMV to remain undetected and undisturbed in the host for significant periods of time 
highlights the importance of virus-host interactions to pathogenesis. However, in immuno-
compromised hosts and newborns, primary CMV infections could cause severe disease 
(Singzer and Jahm, 1996).  Interestingly, MCMV strains (e.g. Smith strain) that are adapted to 
tissue culture are unable to cause lytic or latent infections in immunocompetent or 
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immunocompromised hosts. In contrast, MCMV isolated from saliavary glands of mice 
infected with tissue-culture adapted virus was highly virulent, but the virulence was lost upon 
a single passage through tissue culture (Krmpoti? et al., 2003). 
Human CMV could infect several organs and a wide variety of cell types in vivo and in 
vitro (Myerson et al., 1984; Toorkey and Carrigan, 1989). In cell culture systems, HCMV was 
able to replicate in many different human cell lines, and could infect cells of non-human origin 
although viral DNA replication did not take place (Heieren et al., 1988; Lafemina and 
Hayward, 1988; Tumilowicz, 1990; Ibanez et al., 1991; Waldman et al., 1991). Epithelial, 
endothelial, and fibroblast cells were the primary sites of HCMV infection in vivo, and these 
cells were widely distributed throughout the body (Sinzger et al., 1995). Viral replication and 
antigen production had been observed in epithelial cells of the gastrointestinal tract, 
genitourinary tract, and respiratory tract (Escudero et al., 1992; Sinzger et al., 1995). It has 
been suggested that these epithelial cells may be sources of viral transmission as well as 
infection (Sinzger and Jahn, 1996). Human CMV is transmitted in the population by direct 
contact through bodily fluids such as saliva and urine (Mocarski et al., 2007). In addition, 
transmission from mother to child could occur during birth, via breast milk, or through the 
placenta during pregnancy (Reynolds et al., 1973; Stagno et al., 1980; Dworsky et al., 1983). 
While pathogenesis of MCMV and HCMV is very similar, there is one area in which the two 
viruses differ, as MCMV could not be transmitted across the placenta although the other 
methods of transmission from mother to child are still applicable (Johnson, 1969; Li and 
Tsutsui, 2000). Infection of neonatal mice involved a longer period of lytic infection prior to 
the establishment of latency when compared to adult mice (Reddehase et al., 1994). In 
addition, MCMV infection in neonatal mice could cause damage to the liver, brain, lymphatic 
system, skin, and coronary arteries, as well as inflammation of the heart and skeletal muscles 
(Fitzgerald et al., 1990; Krmpoti? et al., 2003). 
Human CMV could infect endothelial cells of capillaries and venules in several organs 
throughout the body (Wu et al., 1992; Sinzger et al., 1993; Sinzger et al., 1995). Endothelial 
cells had been observed to enter the bloodstream and in this way, could help to disseminate the 
virus (Grefte et al., 1993; Perecivalle et al., 1993). The third main cell type that is a target for 
HCMV infection is the fibroblast, which is located in connective tissues involved in the 
generation of the extracellular matrix. Due to the presence of connective tissues in several 
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organs, infection of fibroblasts could take place in the placenta, lung, and intestines (Sinzger et 
al., 1993; Sinzger et al., 1995). 
Leukocytes or white blood cells such as macrophages, monocytes, granulocytes, and 
lymphocytes were also susceptible to HCMV infection (Taylor-Wiedeman et al., 1991; Gerna 
et al., 1992).  In fact, HCMV infection caused by blood transfusions could be prevented by the 
removal of white blood cells from donors latently infected with the virus (Lang et al., 1977; 
Winston et al., 1980). However, evidence suggested that leukocytes were merely vehicles for 
viral transmission rather than sites of viral replication. Viral DNA could be detected in 
mononuclear cells such as monocytes and their differentiated cell types such as macrophages 
and lymphocytes, as well as polymorphonuclear phagocytes, such as neutrophils (Rinaldo et 
al., 1977; Turtinen et al., 1987; Saltzman et al., 1988; Dankner et al., 1990).  However, some 
viral genes involved in replication were not expressed in these leukocytes (Turtinen et al., 
1987; Grundy et al., 1988). 
Human CMV could use the bloodstream to spread itself from the initial site of 
infection throughout the infected organism (Sinzger and Jahn, 1996). Although the way the 
virus is transmitted from the site of entry into the bloodstream is unknown, studies on MCMV 
indicated that the virus might be transported via phagocytes to other organs (Stoddart et al., 
1994). In addition, monocytes might be involved in the transmission of CMV since they 
became permissive for the virus once they differentiated into macrophages (Ibanez et al., 
1991). 
Human CMV infection in organs could cause disease directly or indirectly. Evidence of 
direct viral involvement in disease was implicated by the presence of high levels of viral 
replication at the site of infection, as well as reversal of symptoms with antiviral therapy 
(Dieterich et al., 1988; Sinzger et al., 1995). Human CMV is believed to cause direct clinical 
consequences in the retina and the gastrointestinal tract, as well as pneumonitis, the 
inflammation of lung tissues (Vasudevan et al., 1990; Heinemann, 1992; Sinzger et al., 1995). 
In certain cases, such as pneumonitis in transplant recipients, the symptoms were not resolved 
through antiviral therapy, and there were no high levels of viral replication in lung tissues 
(Shepp et al., 1985; Zaia et al., 1986). Therefore it is uncertain at this time whether HCMV-
induced host immune response led to pneumonitis. Human CMV infection is believed to 
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indirectly cause liver dysfunction during liver transplantation and alternative blood cell 
formation during hemotopoiesis (Arnold et al., 1992; Theise et al., 1993). 
1.3  Studying viral genetics via the construction of recombinant viruses 
Determining the roles of various viral genes has many important implications towards 
different areas of research in virology. Once the role of a gene is known, it is possible to apply 
this knowledge to study the pathogenesis of the virus, to improve gene therapy protocols, and 
to help develop viral vaccines and treatments for viral diseases (Adler et al., 2003). Disrupting 
the function of a gene can help elucidate the importance of the gene during the viral life cycle. 
In the past, mutations in genes were either induced chemically, or isolated from naturally 
occurring mutants. The functions of these viral genes were often elucidated through in vitro 
experiments away from the context of viral infection. Although this approach will yield some 
useful information about the viral gene in question, oftentimes, viral infection is necessary in 
order to observe the full function of the gene. When genes are studied individually, they often 
behave differently than they do during viral infection. For instance, the products of genes may 
need to interact with each other, or be modified in some way by other viral factors in order to 
carry out their functions during in vitro or in vivo infections. As an example, the CMV 
helicase/primase complex, which is essential for viral DNA replication, is formed by 
interactions between three viral gene products (UL70/M70, UL105/M105 and UL102/M102). 
Therefore, the manipulation of viral genomes is an important tool that can be used to 
introduce mutations or alterations into the viral genome. The biological effects of the 
recombinant virus containing the desired genomic changes can then be observed, either 
through in vitro or in vivo studies. Small viral genomes such as those of Adenoviruses or 
Retroviruses can be easily manipulated using a plasmid-based approach. One of the classical 
methods used to generate recombinant adenoviral genomes was developed by Stow (1981). In 
this method, a plasmid containing mutated DNA sequences in the E1 region of adenovirus was 
ligated in vitro with a restriction fragment representing the rest of the adenovirus genome. The 
ligated DNA was then transfected into a cell line that was able to compensate for the missing 
E1 gene products, and recombinant virus was produced. Thus, the use of plasmid DNA 
enabled the easy manipulation of the adenoviral genome. 
Adenoviral genomes can also be manipulated through homologous recombination in 
vivo. If a plasmid vector containing the adenoviral genome with an insert in the E1 region was 
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co-transfected with another plasmid containing a wild-type or altered E1 region, homologous 
recombination in vivo occurred between the two plasmids (McGrory et al., 1988). Although 
adenoviruses could package sequences into virions that are 5% larger than the viral genome, 
the insert in the E1 region made the parental virus larger than the packaging limit (McGrory et 
al., 1988). Therefore, recombinant adenoviruses containing the desired alterations in the E1 
region were preferentially packaged and rescued. However, this method required more 
extensive plaque purification compared to other methods in order to separate the recombinant 
virus from wild-type (Stow, 1981; McGrory et al., 1988). 
Due to the low efficiency of recombination in vivo in a mammalian system, methods 
have been developed that enable the recombination to take place prior to transfection of viral 
DNA into mammalian cells (Ketner et al., 1994; Chartier et al., 1996; Crouzet et al., 1997). 
The first method involved the construction of a YAC (yeast artificial chromosome) containing 
the adenovirus genome in yeast spheroplasts (Ketner et al., 1994). Homologous recombination 
could occur in yeast between the adenovirus YAC and linearized plasmid DNA containing 
mutated adenoviral genes, followed by the transfection of YAC DNA into cells to produce 
infectious virus (Ketner et al., 1994). Advantages of the YAC method over the in vivo 
homologous recombination method are that mutations can be placed anywhere in the genome 
regardless of restriction site availability, and homologous recombination in yeast is very 
efficient. Moreover, since the recombinant YAC can be characterized before transfection, the 
recovered recombinant virus does not need to be plaque-purified as extensively. 
In a similar manner, recombinant adenoviral genomes could be constructed via 
homologous recombination in E. coli prior to transfection of mammalian cells with viral DNA 
to produce viable virus. Recombination occurred in a recombination-competent (RecA+) 
bacterial strain between a plasmid vector containing the adenoviral genome and DNA 
containing the desired mutated sequence flanked by homologous viral sequences. The 
recombinant adenoviral DNA was then transformed into a RecA- bacterial strain in order to 
generate higher yields of DNA with increased stability. For example, the adenoviral genome 
on the plasmid used by Chartier et al. (1996) was flanked by PacI sites (absent from the 
genome) so that it could be excised by digestion with PacI prior to transfection into 
mammalian cells to produce recombinant virus. The advantages of homologous recombination 
in E. coli are that any region of the viral genome can be altered, and the frequency of isolating 
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correct recombinants is high. Thus, transfection of the resulting recombinant viral genome into 
mammalian cells would allow the rescue of the expected recombinant virus with high 
probability (Chartier et al., 1996). Although the above method was initially used to manipulate 
the E1 region of the adenoviral genome, a subsequent method described the mutagenesis of 
any region of the genome (Crouzet et al., 1997). However, since the latter method required a 
two-step cloning strategy and resolution of cointegrates containing both the adenoviral genome 
and a plasmid with the desired mutation, viral revertants would be produced, and a screening 
process was necessary to distinguish between wild-type and recombinant adenoviral genomes. 
Another method for manipulating viral genomes involved the incorporation of viral 
DNA fragments into a P1 cloning vector that was packaged into bacteriophage P1 in vitro 
(Sternberg, 1990). Bacteriophages were then injected into E. coli and the DNA was 
circularized by the action of the P1 loxP recombination sites present on the vector and the P1 
Cre recombinase present in bacterial cells (Sternberg, 1990). However, the bacteriophage P1 
system was limited by the maximum insert size of 100 kbp dictated by the in vitro packaging 
system (Sternberg, 1990; Ioannou et al., 1994). A cloning system based on both the BAC 
(bacterial artificial chromosome) and bacteriophage P1 methods called P1-derived artificial 
chromosomes could accommodate inserts between 100-300 kbp (Ioannou et al., 1994). In this 
system, a vector containing a SacB gene was used for selection of recombinant DNA clones 
derived from bacteriophage P1, and the DNA was transformed into E. coli by electroporation 
(Ioannou et al., 1994). 
1.3.1 Methods for constructing recombinant herpesvirus genomes 
Herpesviral genomes are large and cannot be manipulated using plasmids. There are 
two general strategies for introducing alterations into herpesviral genomes via homologous 
recombination. The first involved in vivo homologous recombination that could be 
accomplished either by insertional mutagenesis or co-transfection of overlapping cosmid 
clones.  The second used a BAC-based system so that homologous recombination could take 
place in bacterial cells prior to the rescue of recombinant virus in cell culture. The BAC 
method has significant advantages over the in vivo methods as mutations can be introduced 
into any viral gene, including essential genes, since construction of the recombinant viral 
genome takes place in vitro, and is not dependent on the rescue of viable virus in vivo. 
Moreover, the viral genome can be characterized before time is spent isolating recombinant 
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virus (Messerle et al., 1997). In addition, very large DNA fragments (over 300 kbp) can be 
incorporated into the BAC vector. Thus even the large MCMV or HCMV genomes could be, 
and have been, cloned as a BAC (Messerle et al., 1997; Brune et al., 2000). 
As mentioned earlier, YACs provided an alternative method of constructing 
recombinant viral genomes. Although a YAC cloning vector could incorporate much larger 
DNA sequences (up to 2 Mbp) than BACs, there are several reasons the BAC system is 
preferable over YACs (Ramsay, 1994; Brune et al., 2000). It is commonly known that more 
than one YAC could be transformed into a single yeast cell, perhaps because of the high DNA 
concentrations used to circumvent the low transformation efficiency of yeast (Schalkywk et 
al., 1995). On the other hand, BACs could be transformed into E.coli at high efficiencies by 
electroporation at a copy number of 1-2 per cell (Shizuya et al., 1992). Therefore, a significant 
percentage of isolated YAC clones contained chimeras produced by recombination between 
the multiple YACs transformed into the same cell, whereas very few BAC clones were 
produced as chimeric molecules (Shizuya et al., 1992). Whereas YACs were maintained as 
linear molecules, BACs were maintained as circular plasmids that facilitated the handling of 
the DNA, and decreased the possibility of shearing the large DNA molecules (Shizuya et al., 
1992). Bacterial artificial chromosomes characterized by restriction analysis were found to be 
much more stable than YACs, which often suffered deletions within the inserted sequences 
(Shizuya et al., 1992; Monaco and Larin, 1994). The use of recombination-defective strains 
could decrease the possibility of unexpected genome alterations. However, this also resulted in 
decreased transformation efficiency (Schalkwyk, 1995). In addition, there was great difficulty 
in purifying YAC DNA away from yeast chromosomal DNA, which was not the case for 
BACs (Schalkwyk et al., 1995). 
1.3.1.1 In vivo complementation 
Since homologous recombination is a rare event in mammalian cells, strategies to 
select for recombinant viruses need to be developed. Often the region of the viral genome one 
is interested in investigating contains no readily available selectable markers (Post and 
Roizman, 1981). Therefore, markers such as beta-galactosidase or beta-glucuronidase could be 
inserted into the genome at specific sites as a way to either inactivate viral genes or isolate 
viral recombinants containing the desired alterations (Jones et al., 1991; Takekoshi et al., 
1991). However, the selection of recombinants using these 2 markers is carried out after virus 
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is produced, in contrast to the use of neo, thymidine kinase (TK) or E. coli gpt genes as 
selection markers, which conferred growth advantages to the desired recombinant viruses and 
increased the probability of success (Post and Roizman, 1981; Wolff et al., 1993; Greaves et 
al., 1995). Both TK and gpt could also be selected against, thereby providing the investigator 
with the option to select for the absence of these markers in recombinant viruses. To 
completely eliminate the necessity of incorporating foreign sequences such as marker genes 
into the viral genome, a method was developed where recombinant viruses could be produced 
through co-transfection of cloned overlapping DNA fragments encompassing the entire viral 
genome into susceptible cells (van Zijl et al., 1988). Homologous recombination in vivo 
resulted in the reconstitution of full-length viral genomes containing the desired alterations and 
the rescue of viable recombinant viruses. 
1.3.1.1.1  Insertional mutagenesis 
Insertional mutagenesis involves the insertion of a sequence into a gene to render it 
nonfunctional. This is often accomplished by co-transfection of viral DNA with a plasmid 
containing a selection marker flanked by homologous viral sequences to target a region of 
interest on the viral genome. Homologous recombination in vivo results in the replacement of 
the wild-type gene with a nonfunctional mutant. 
The insertion of beta-galactosidase into a viral gene enables the identification of viral 
recombinants containing the interrupted gene through a colorimetric assay. Briefly, cells 
infected with virus recovered from the transfection were overlaid with agarose containing X-
gal (5-bromo-4-chloro-3-indolyl- beta-D-galactopyranoside), and recombinants that had 
incorporated the beta-galactosidase marker into their genomes could be isolated from blue 
plaques (Takekoshi et al., 1991). This method has been used to identify several viral genes that 
were not required for growth in cell culture, including HCMV UL18, UL16, and MCMV ie2 
(Manning and Mocarski, 1988; Browne et al., 1992; Kaye et al., 1992). Recombinant viruses 
containing genes disrupted by beta-galactosidase insertion were stable, with a low rate of 
reversion. However, the disadvantage of this method is that when an essential gene has been 
disrupted this way, viable virus cannot be isolated (Manning and Mocarski, 1988). 
A similar technique was developed using the beta-glucuronidase gene and resulted in 
the production of stable recombinants (Jones et al., 1991). Initial concerns that beta-
glucuronidase could not be used as a marker gene due to the presence of high levels of 
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endogenous beta-glucuronidase were unfounded, and this method was used to demonstrate that 
the HCMV US10 and US11 genes were not required for in vitro replication (Jones et al., 
1991). However, the frequency of recombinant production was only 5%, compared to a 
frequency of 10% when beta-galactosidase was used (Jones et al., 1991; Takekoshi et al., 
1991). It was suggested that the smaller size of the beta-glucuronidase gene (1.9 kb) compared 
to beta-galactosidase (3.1 kb) might decrease the probability of unexpected deletions in the 
recombinant viral genome if the packaging limits was exceeded (Jones et al., 1991). 
Although the expression of beta-galactosidase or beta-glucuronidase allowed for the 
identification of viral recombinants, there was no selection pressure when virus recovered after 
transfection was allowed to spread. Since propagation of wild-type virus alongside the desired 
recombinants could not be prevented during the isolation process, several cycles of plaque 
purification were required to minimize the contamination of recombinant virus stocks with 
wild-type virus. In addition, it is possible that even following several cycles of plaque 
purification and selection, reversion to a wild-type phenotype may occur, as no selection for 
the recombinant phenotype is applied during the propagation of the recombinant virus (Wolff 
et al., 1993). 
A method of creating recombinant HCMV by insertional mutagenesis which does 
involve selection during viral growth utilizes the bacterial neo gene.  This gene encodes a 
neomycin/kanamycin phosphotransferase and could be inserted into the viral genome via 
homologous recombination (Wolff et al., 1993). After transfection into mammalian cells, the 
progeny virus was used to infect cells grown in the presence of G418, which selected for the 
presence of the neo gene (Wolff et al., 1993). The virus was further purified through additional 
passages in media containing G418. This method has been used to create HCMV mutants, and 
it was observed that following the initial selection, 20% of the virus pool represented 
recombinant virus (Wolff et al., 1993). After 3 passages in the presence of G418, all viruses 
isolated through plaque purification had incorporated the neo gene into their genomes. The neo 
selection method is relatively quick compared to the colorimetric methods, and selects for 
stable recombinants during virus propagation (Wolff et al., 1993). However, selection for neo 
resulted in the death of uninfected cells (Greaves et al., 1995). 
Insertional mutagenesis using TK as a selectable marker has one important advantage 
over the neo gene, as the investigator can choose to select for, or against TK (Post and 
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Roizman, 1981). To introduce specific mutations into the viral genome, two selection steps 
were required. The first step involved the insertion of TK into the target gene through 
homologous recombination between the viral genome and a plasmid containing the TK gene 
flanked by viral sequences homologous to the target gene. The TK-expressing virus was 
selected from the pool of recovered viruses by plating these viruses on TK- cells in media 
containing hypoxanthine, thymidine and methotrexate. In the second step, cells were co-
transfected with DNA from the TK-expressing virus produced in the first step and a plasmid 
containing the mutated or wild-type target gene. Selection against TK was applied by 
propagating the virus in the presence of thymidine arabinoside, which was toxic to cells 
expressing thymidine kinase. Thus recombinant virus incorporating the desired mutation via 
homologous recombination, but lacking TK would be recovered preferentially (Post and 
Roizman, 1981). 
Although this is a useful method for the construction of recombinant viruses, there are 
disadvantages to this procedure. Most notably, insertional mutagenesis using the TK gene 
requires the availability of mutant cell lines deficient in TK (Mulligan and Berg, 1981). In fact, 
the limited host range of HCMV and the lack of permissive TK- human cell lines is the reason 
the TK selection procedure has not been adapted for CMV mutagenesis, and the development 
of alternative selection schemes are required (Greaves et al., 1995). In addition, insertional 
mutagenesis using the TK gene can only be applied to viral genomes that lack the TK gene, 
further limiting the utility of this approach. 
The E. coli gpt gene, which encodes a xanthine-guanine phosphoribosyltransferase, is 
another selectable marker that allows for both positive and negative selection. During positive 
selection, cells were infected with wild-type virus and then transfected with a plasmid 
containing the gpt gene flanked by sequences homologous to the target gene, resulting in the 
insertion of the gpt gene into the viral genome via homologous recombination. Selection for 
recombinants expressing gpt was carried out by propagating the virus in media containing 
mycophenolic acid (an inhibitor of de novo purine synthesis), xanthine, and adenine (Mulligan 
and Berg, 1981). If specific alterations of the target gene were desired, an additional step 
involving selection against gpt was performed. Cells deficient in mammalian hypoxanthine 
phosphoribosyltransferase were transfected with a plasmid containing the target gene with the 
desired deletion or mutation, and infected with recombinant virus containing the gpt insertion. 
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Recovered virus was propagated in media containing a toxic guanine analog (6-thioguanine), 
which allowed selection against viruses expressing gpt. Therefore, only viruses that had 
undergone homologous recombination and incorporated the desired alterations would be 
preferentially recovered. 
The gpt gene can be used as a selection marker in many different cell lines and has 
widespread utility as a way to construct recombinant viruses. Selection utilizing E. coli gpt is 
efficient enough that cells can be infected by virus, and then transfected with plasmid DNA 
containing the marker genes flanked by homologous viral sequences, or vice versa (Vieira et 
al., 1994). Cell death did not occur as a result of gpt selection and thus, in contrast to selection 
by G418 resistance, recombinant virus could be isolated by plaque purification (Greaves et al., 
1995). 
As an example, Greaves et al. (1995) demonstrated that the E. coli gpt selection 
technique could be used to modify genes either through insertion of the gpt gene, rendering the 
viral gene non-functional, or by deletion of the gene. The gpt gene was inserted into HCMV 
US3, and deletion mutants lacking regions from the IRS1 and US3-US5 genes were generated 
(Greaves et al., 1995). Some resistance towards selection with 6-thioguanine was observed, 
resulting in the growth of gpt containing viruses. The authors determined that these revertant 
viruses had acquired mutations or deletions in the gpt gene, thereby allowing their propagation 
in the presence of the toxic compound (Greaves et al., 1995). However, they were able to solve 
this problem by hybridization with a gpt probe to screen for recombinant viruses that did not 
contain the gpt gene. 
Although the techniques of insertional mutagenesis utilizing marker genes are useful in 
studying functions of various herpesvirus genes, particularly HSV-1 genes, there are several 
key limitations to this approach. First, virus generated through homologous recombination in 
vivo required selection against wild-type virus (Wagner et al., 2002), and the selection of virus 
mutants with a growth disadvantage against their wild-type parents could be inefficient 
(McGregor and Schleiss, 2001). Second, insertional mutagenesis could not be used for 
constructing recombinant viruses containing lethal mutations in an essential gene. Lastly, it 
has been noted that the presence of the marker gene in the viral genome may in fact have an 
impact on the phenotype of the recombinant virus and the ability to recover the virus mutant 
(Kemble et al., 1996; Ehsani et al., 2000). 
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1.3.1.1.2  Construction of recombinant virus from cloned overlapping fragments 
There are two methods of producing recombinant virus through cloned overlapping 
viral DNA fragments. One is a purely cosmid-based system, while the other uses both cosmids 
and plasmids. The cosmid-based system involved the generation of a set of cosmids containing 
overlapping subgenomic fragments that span the entire viral genome. When these cosmids 
were co-transfected into cells, viable virus could be recovered via homologous recombination 
in vivo between overlapping regions of the viral genome. The second system worked 
essentially in the same way, except that one of the cosmid clones was replaced with a set of 2 
plasmids, which overlapped with each other and contained the desired mutation. The use of 
plasmids made it easier to manipulate viral DNA fragments and introduce point mutations into 
large herpesvirus genomes. 
The cosmid co-transfection approach did not involve the insertion of marker genes into 
the viral genome (McGregor and Schleiss, 2001). Unlike insertional mutagenesis, which 
usually allowed one gene to be altered at a time, the cosmid-based system could be used to 
introduce multiple alterations to the viral genome in one experiment (van Zijl et al., 1988). In 
this system, the viral genome was re-constituted solely via homologous recombination in vivo 
between the available cosmids, so any virus produced should contain all the desired mutations, 
thereby minimizing the number of steps required for recombinant virus isolation (Cohen and 
Seidel, 1993). 
However, this protocol still has several disadvantages. Finding unique restriction sites 
in the large cosmids to use for genetic manipulation is difficult, and reconstitution of the viral 
genome in cell culture required several recombination events that could lead to unexpected 
genome alterations (Brune et al., 2000; McGregor and Schleiss, 2001). Furthermore, 
maintaining stable cosmid clones with large viral DNA inserts containing multiple repeat 
elements might be problematic, since these sequences were known to be susceptible to 
rearrangements or deletions (Kim et al., 1992). In addition, construction of revertant viruses to 
ascertain that the phenotype observed in the recombinant virus is due to the expected mutation 
is laborious (Brune et al., 2000). The determination of whether the correct recombinant had 
been created could only be performed after the virus was isolated and grown up in cell culture 
(Messerle et al., 1997). Several examples of the utility of this approach to herpesvirus 
mutagenesis are described below. 
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Overlapping cosmid and plasmid clones were used to generate recombinant HSV-1 
containing point mutations in UL26 (Register and Shafer, 1996). These point mutations could 
be reverted back to wild-type sequences, and the revertant viruses were shown to be identical 
to wild-type HSV-1. This demonstrated that no unexpected second-site mutations occurred, 
and the observed phenotype of the recombinant HSV-1 was indeed due to the point mutation 
introduced (Register and Shafer, 1996). Furthermore, work done by Ehsani et al. (2000) 
demonstrated that the in vitro and in vivo growth characteristics of MCMV reconstituted from 
a set of 7 cosmids were comparable to those of wild-type MCMV. There was no incorporation 
of cosmid vector sequences or the presence of unwanted secondary mutations or genome 
rearrangements in the reconstituted MCMV genome (Ehsani et al., 2000). 
A set of 8 overlapping cosmid clones was used to regenerate the 230 kbp HCMV 
genome (Kemble et al., 1996). Furthermore, this method was used to construct a chimeric 
virus in which a 13 kbp DNA fragment from a virulent strain of HCMV (Toledo) replaced the 
corresponding region of the avirulent Towne viral genome. A change in plaque morphology 
was observed as a result of this genome alteration (Kemble et al., 1996). Cihlar et al. (1998) 
used a set of 7 cosmid clones and 2 overlapping plasmids to generate recombinant HCMV, and 
observed that this approach was just as efficient as the use of 8 cosmid clones even though the 
regions of overlap were shorter. A recombinant virus containing more than one mutation in 
UL54 was constructed and the usefulness of the cosmid co-transfection technique was 
demonstrated (Cihlar et al., 1998). 
1.3.3.2  Construction of recombinant viral genomes using bacterial artificial 
chromosomes 
The BAC cloning vector developed by Shizuya et al (1992) is based on the F (fertility) 
factor plasmid from E. coli. This vector contains the F factor oriS and repE genes, which are 
involved in monitoring replication, and parA and parB genes, which have the function of 
ensuring a low copy number of 1-2 per cell (Shizuya et al., 1992). In addition, the BAC vector 
contains a chloramphenicol resistance gene to allow for antibiotic selection (Shizuya et al., 
1992). 
Three strategies for constructing recombinants with BAC vectors are described below: 
the shuttle plasmid method, the recE/recT method, and a method involving a defective lambda 
prophage. All of these methods take advantage of the efficiency of homologous recombination 
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in bacteria, which is much higher than that of similar reactions in mammalian cells in vivo. 
The general steps in constructing recombinant herpesviruses via BAC vectors include the 
insertion of BAC vector sequences into the viral genome by in vivo homologous 
recombination, mutagenesis of the BAC through homologous recombination in E. coli, and 
reconstitution of viable virus in mammalian cells (Messerle et al., 1997). The DH10B strain of 
E. coli is generally regarded as the preferred bacterial strain for stable maintenance of BACs. 
This bacterial strain has high transformation efficiency and a recA mutation that renders it 
deficient for recombination. In addition, it contains mutations that allow methylated DNA 
sequences and large plasmids to be stably maintained (Ioannou et al., 1994). 
Homologous recombination with a shuttle plasmid is a two-step process where a 
cointegrate was initially formed between a plasmid containing the mutated gene and a BAC 
containing the viral genome. The shuttle plasmid contained a temperature sensitive origin of 
replication, and its replication could be inhibited by increasing the temperature from 30°C to 
42°C (Wagner et al., 2002). Subsequently, the cointegrate was resolved, producing either wild-
type virus or a mutated viral genome (Wagner et al., 2002). The recombination reaction took 
place in an E. coli strain containing a temperature-sensitive recA gene, thereby allowing the 
reaction to be tightly controlled (Brune et al., 2000). The first herpesvirus genome to be cloned 
as an infectious BAC was the 230 kbp MCMV genome (Messerle et al., 1997). The authors 
constructed a mie1 mutant and demonstrated that the BACs remained stable after several 
weeks of propagation in bacteria (Messerle et al., 1997). 
Although Messerle et al. (1997) demonstrated that BAC vectors could be successfully 
used for the construction of MCMV mutants, these viruses contained BAC vector sequences as 
well as a deletion in a region of the genome nonessential for viral replication in vitro. Both 
alterations to the viral genome could affect the in vivo replication of MCMV. In fact, Wagner 
et al. (1999) investigated the in vivo growth properties of wild-type MCMV and the 
recombinant MCMV mutant produced by Messerle et al. (1997), and they found that the 2 
viruses showed significant differences during viral infection and the MCMV mutant was much 
less virulent (Wagner et al., 1999). 
Wagner et al (1999) used the strategy illustrated in Figure 1.2 to re-insert the deleted 
MCMV sequences into the viral genome already present in the BAC vector via homologous 
recombination, resulting in a new MCMV BAC where the BAC vector sequences were 
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flanked by duplicate viral sequences. The presence of these flanking sequences enabled the 
removal of vector sequences from the MCMV genome by homologous recombination in vivo. 
The smaller viral genomes resulting from the loss of vector sequences were preferentially 
packaged over several passages in tissue culture, and wild-type MCMV was recovered 
(Wagner et al., 1999). The authors were able to distinguish between wild-type MCMV (Smith 
strain) and the reconstituted virus because the re-inserted sequence was derived from the K181 
strain of MCMV, and contained a point mutation not present in the Smith strain of MCMV. 
Wagner et al. (1999) then compared the growth properties of wild-type and recombinant 
MCMV viruses in mice, and demonstrated that removal of the BAC vector sequences coupled 
with the re-insertion of the missing MCMV sequences resulted in disease progression 
comparable to that of wild-type MCMV (Wagner et al., 1999). 
An additional example highlighted the importance of carefully selecting the site of 
BAC vector insertion into the viral genome. During recombinant virus construction, F plasmid 
vector sequences were inserted into the gG locus of the pseudorabies virus genome, a region 
believed to be nonessential for both in vitro and in vivo infection. Although the behavior of 
wild-type and recombinant pseudorabies viruses were similar during in vivo infection, the F 
plasmid sequences were spontaneously deleted during the DNA transfection process. 
Interestingly, insertion of F plasmid sequences at another locus did not result in spontaneous 
deletion, demonstrating that the stability of the recombinant viral genome might depend on the 
site of insertion of vector sequences (Smith and Enquist, 1999). 
Brune et al. (1999) developed an alternative approach to targeted mutagenesis by 
mutagenizing the MCMV genome via random transposon insertion. This was accomplished by 
growing a recA- strain of E. coli harboring a MCMV BAC and a temperature-sensitive 
transposon donor plasmid at 30°C under antibiotic selection for both components. Bacteria 
were spread on plates containing antibiotics that selected for BACs with transposon insertions 
and grown at 42°C so that replication of the donor plasmid was inhibited (Brune et al., 1999). 
The BAC DNA isolated from the resultant bacterial clones was analyzed by restriction enzyme 
digestion and direct sequencing. It was observed that 90% of the clones contained transposon 
insertions. The viability of these transposon mutants was evaluated in cell culture. If infectious 
virus was recovered after transfection, the insertion should be in a gene nonessential for 
MCMV replication in cell culture. In contrast, if an essential gene were inactivated by 
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transposon insertion, viable virus would be recovered only by co-transfection with DNA 
containing a functional copy of the disrupted gene. In addition, revertant viruses produced by 
homologous recombination with wild-type MCMV sequences in bacteria restored the parental 
phenotype of these mutants. The genomes of these transposon mutants were stable, and this 
procedure provided a useful way for quickly identifying essential and non-essential genes in 
MCMV (Brune et al., 1999). 
Another way of manipulating viral genomes in BACs utilized linear DNA fragments 
instead of plasmids to introduce a specific mutation into the viral genome via homologous 
recombination. The recombination functions were mediated either by the E. coli recE and recT 
genes, the lambda red? and red? genes (Zhang et al., 1998; Muyrers et al., 1999), or a 
defective lambda prophage (Yu et al., 2000; Lee et al., 2001b). The recE/recT or red?/red? 
recombination genes were located on a plasmid that was transferred into a recA- recBC+ strain 
of E. coli. The bacteria also harbored the target DNA sequence on a BAC. Linear DNA 
containing the mutated gene of interest and an antibiotic resistance gene was then transformed 
into E. coli cells, where a successful homologous recombination reaction would result in the 
insertion of the desired mutation into the viral genome. Typically, homology arms of 1-3 
kilobases were required on either side of the gene of interest for the homologous 
recombination reaction to occur. However, the recombination system described here required 
only short homology regions of 25-50 nucleotides at both ends of the linear DNA for the 
reaction to proceed efficiently (Zhang et al., 1998; Muyrers et al., 1999; Wagner et al., 2002). 
In order for recE/recT or red?/red? mediated recombination to occur in recBC+ strains 
of E. coli, the RecBCD exonuclease must be inhibited by Red? (gam) to prevent premature 
degradation of the linear DNA fragment carrying the mutated gene. Therefore, plasmids 
harboring these genes also contained gam as well as an arabinose inducible promoter for recE 
or red?. In this way, the recombination reaction could be initiated by the addition of a 
chemical inducer (Zhang et al., 1998; Muyrers et al., 1999). 
A major advantage of this method is that the recombination reaction can be carried out 
in the recA- bacterial strains used to maintain the BACs (Messerle et al., 1997; Muyrers et al., 
1999), since the recombination reaction is independent of recA function. In addition, the 
recE/recT or red?/red? recombination system did not require the presence of convenient 
restriction sites to facilitate the cloning or excision of the target DNA sequence. Instead, linear 
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DNA fragments used to introduce mutated sequences into the viral genome could be generated 
conveniently by PCR (polymerase chain reaction) (Zhang et al., 1998; Muyrers et al., 1999; 
Wagner et al., 2002; Adler et al., 2003). 
One of the disadvantages of the recE/recT or red?/red? mediated recombination 
system is the necessity of removing the antibiotic resistance gene that was inserted into the 
viral genome via an unavoidable double crossover event. Removal of these sequences by site-
specific recombinases could be facilitated by flanking the antibiotic resistance gene with FRT 
(FLP target recognition) or loxP sites (Zhang et al., 1998). However, this process inevitably 
left a “scar” (short foreign DNA sequences) at the site of recombination that might affect the 
biological properties of the recombinant virus. Another potential problem concerned the 
stability of the BACs that are normally maintained in recA- bacteria. However, plasmid 
expression systems such as the ones described here are often leaky. In addition, herpesvirus 
genomes are known to contain multiple direct repeat sequences. Thus, even the presence of 
low levels of these powerful recombination genes in bacteria has the potential to cause BAC 
instability (Brune et al., 2000; Lee et al., 2001b). 
As an alternative to maintaining a plasmid with the required recombination genes in 
bacteria, an E. coli strain that harbored a lambda prophage was constructed so that expression 
of the recombination genes gam, exo, and bet could be controlled by a temperature-sensitive 
cI-repressor (Yu et al., 2000; Lee et al., 2001b). In this system, expression of the 
recombination genes was briefly induced at 42°C, and the temperature shifted back down to 
32°C. This was sufficient to mediate efficient homologous recombination between the target 
and BAC DNAs, requiring only short homology arms of ~40 bases at both ends of the target 
DNA fragment. To create the DY380 strain of E. coli for this purpose, Lee et al. (2001b) 
transferred a lambda prophage containing a tetracycline resistance marker (tetR) into DH10B 
bacteria and demonstrated that this prophage-based system functioned with the same or better 
efficiency as the plasmid-based recE/recT system. Furthermore, the DY380 bacteria could be 
modified to facilitate the removal of selectable markers from BAC constructs via site-specific 
recombination at FRT or loxP sites. This was accomplished by replacing the tetR gene on the 
prophage with the araC regulatory gene, thereby allowing precise control over the expression 
of arabinose-inducible genes flpe and cre. 
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1.4  Previous work performed in our laboratory 
Our laboratory was involved in studying murine cytomegalovirus as an animal model 
for cytomegalovirus infections since its establishment in 1983. Our goal is to understand the 
molecular mechanism underlying the host specificity of cytomegaloviruses as well as develop 
anti-viral therapies that can be extended to the treatment and prevention of HCMV infections. 
To this end, we have characterized a panel of monoclonal and polyclonal antibodies specific 
for a number of viral gene products (Loh et al., 1988; Loh and Qualtiere, 1988; Loh, 1989; 
Loh, 1991; Loh et al., 1991; Ph.D. thesis: Q. Wu, 1998; Scalzo et al., 2004). Using these 
reagents, we have identified MCMV gB, gH, and gp24 (gpM73.5) as targets for neutralizing 
monoclonal antibodies and potential candidates for vaccine development. In addition, both 
cDNA and genomic DNA libraries have been constructed and used successfully in the 
isolation and characterization of MCMV genes (Loh et al., 1994; Scalzo et al., 2004). 
More recently, we have constructed recombinant MCMV by conventional in vivo 
complementation methods. In particular, we have constructed and characterized M73.5 null 
and glycosylation mutants to study the role of this glycoprotein in the virus life cycle 
(manuscript in preparation). Furthermore, we have constructed a chimeric MCMV by 
replacing the MCMV M44 (DNA polymerase processivity factor) gene with its HCMV 
homolog (UL44) in our initial attempt to replace MCMV replication genes with their HCMV 
homologs and facilitate the in vivo testing of anti-viral drugs targeting the HCMV DNA 
polymerase complex. We also anticipate that the production of similar chimeric MCMVs may 
play an important role in elucidating the mechanism of CMV host specificity. As a result, we 
began to explore and develop methodologies that would simplify and facilitate rapid and 
efficient construction of recombinant MCMV. 
During the last 5 years, we have modified an existing method of constructing 
recombinant MCMV using BAC vectors. This strategy makes use of a recombinant MCMV 
where the unique SwaI site has been destroyed, and specific mutations can be introduced into 
any part of the MCMV genome in a 2-step process. The details of this procedure will be 
described in greater detail in the Results section. We have now successfully constructed M73.5 
mutants and M44/UL44 chimeric MCMV with this approach. Preliminary results demonstrated 
that these recombinant MCMVs behaved similarly to those constructed by more 
“conventional” in vivo methods. However, the effect of the SwaI mutation introduced into the 
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“backbone” of these recombinant murine cytomegaloviruses has not yet been tested. In this 
thesis, I intend to provide preliminary evidence to demonstrate that the biological properties of 
the virus are not affected by the SwaI mutation. 
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2.0  RATIONALE AND OBJECTIVES 
Our laboratory has used MCMV as a model for HCMV to explore the molecular 
mechanisms underlying the host specificity of cytomegaloviruses as well as develop anti-viral 
therapy/vaccines by studying the roles played by viral genes involved in these processes. Thus 
the ability to manipulate the MCMV genome and introduce specific mutations into viral genes 
efficiently became an important part of our research program. Recently, we have utilized a 
modified MCMV (Smith strain) genome in which the unique SwaI site has been destroyed as 
the “backbone” for specific mutagenesis of the viral genome. Subsequently we have 
successfully constructed several recombinant MCMV mutants and demonstrated the potential 
usefulness of this methodology. 
In this thesis, I investigated whether the SwaI mutation introduced into the MCMV 
genome affects the growth properties of MCMV in tissue culture. In addition, I demonstrated 
that the SwaI mutation can be reversed, and the revertant virus has growth properties similar to 
the standard Smith strain of MCMV. 
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3.0  MATERIALS AND METHODS 
3.1  Cell lines 
3.1.1  Balb/3T3 clone A31 (ATCC CCL 163) 
The Balb/3T3 cell line was originally derived from mouse embryo cultures of inbred 
Balb/c mice and is very similar to mouse 3T3 fibroblasts (Aaronson and Todaro, 1968).  Since 
Balb/c mice were used in most laboratories as an animal model for studying permissive 
MCMV replication in vivo, these cells were used for experiments on the growth properties of 
recombinant and wild-type MCMV. 
 3.1.2  3T3-L1 (ATCC CL-173) 
The 3T3-L1 cell line is a cloned subline of the mouse fibroblast line 3T3 that 
accumulates lipids (Green and Kehinde, 1974).  These cells were used for plaque assays and 
the isolation of viral DNA from infected cells (sections 3.1.5 and 3.7) as well as large scale 
propagation of MCMV stocks. 
3.1.3  COS-1 (ATCC CRL 1650) 
COS-1 is a simian cell line that was developed through the transformation of CV-1 
cells with a defective mutant of SV40 (Gluzman, 1981).  These cells were used for the analysis 
of the growth of recombinant and wild-type MCMV in semi-permissive cells. 
 3.1.4  Cell culture and passage 
Cell lines were maintained in Dulbecco’s Minimum Essentials Media (DMEM, 
Invitrogen Canada, Inc) containing 10% Fetal Calf Serum (FCS, Invitrogen Canada, Inc) in a 
humidified NAPCO Incubator (Precision Scientific, Inc., Chicago, IL) at 37°C with 5% CO2. 
Once cells were confluent, the old media were aspirated. Then cells were rinsed with GKNP 
balanced salt solution (0.8% (w/v) NaCl, 0.04% (w/v) KCl, 0.006% (w/v) Na2HPO4
.H2O, 
0.006% (w/v) KH2PO4, 0.1% (w/v) glucose, 0.002% (w/v) phenol red, pH 7.0) and treated with 
trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA; 0.025% trypsin and 0.27 mM EDTA 
in GKNP).  After cells were trypsinized, they were resuspended in fresh DMEM and generally 
split at a dilution of 1:10 at 3 day intervals. 
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3.2  Viruses 
3.2.1  Virus strains 
The Smith strain of MCMV (ATCC VR-194) was obtained from the American Type 
Culture Collection, Rockville, MD and used as a standard for comparison with recombinant 
virus in all experiments. The MCMV-EGFP virus was rescued after transfection of 
pMCMV_EGFP BAC DNA (obtained from Dr. Jay Nelson of Oregon Health Sciences 
University) into Balb/3T3 cells. The recombinant viruses MCMV-ETwt and MCMV-ETSwa- 
were recovered after transfection of pMCMV_ETwt and pMCMV_ETSwa-* DNA into 
Balb/3T3 cells. Schematics for these recombinant viruses are shown in Figure 3.1. 
3.2.2  Plaque assays 
When 3T3-L1 cells in 35 mm tissue culture dishes were 75-80% confluent, they were 
infected in duplicate with at least two sets of 10 fold dilutions of each virus sample. After 
absorption for 1-2 hours at 37°C, the media were removed, and cells were overlaid with 2 mL 
of DMEM containing 0.5% (w/v) agarose, 2.5% (v/v) FCS, and 40 μg/mL gentamycin. The 
media were allowed to solidify and the plates incubated in a CO2 incubator at 37°C.  Plaques 
were generally counted between 5 to 7 days post-infection. 
3.2.3  Analysis of viral growth properties 
For the analysis of viral growth properties, Balb/3T3 or COS-1 cells in 35 mm tissue 
culture dishes were infected with wild-type or recombinant MCMV at an appropriate MOI 
when cells were about 60% confluent.  The virus was allowed to absorb for 1 hour at 37°C 
before cells were washed four times with DMEM to remove unbound virus.  Cells were 
subsequently incubated in DMEM containing 2.5% FCS at 37°C.  At each time point, 1 mL of 
media was removed for plaque assays and cells were supplemented with 1 mL fresh media. 
3.2.4  Virus production and purification 
To produce high titer stocks of MCMV for infection experiments, 10 x 150 mm plates 
of 3T3-L1 cells were infected with recombinant or wild-type MCMV at low multiplicities of 
infection. Infection was allowed to proceed until virtually 100% of the cells exhibited 
cytopathic effects. Supernatants containing MCMV were collected and centrifuged at 4000 x g 
for 20 minutes to remove cellular debris. Then virus was pelleted at 15000 x g for 3 hours, 
resuspended in 5 mL of DMEM supplemented with 5% FCS, and stored in 1 mL aliquots at 
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Figure 3.1  Schematics of recombinant MCMVs 
The HindIII restriction maps of the recombinant MCMVs relevant to this thesis are shown. 
Expanded views of the modified EcoRI-T and EcoRI-E fragments in MCMV-ETSwa- and 
MCMV-EGFP are shown above or below the respective viral genomes. These fragments are 
labeled with an asterisk (*) to d istinguish them from wild-type fragments. The numbers 
between restriction sites represent the sizes of the subfragments in kilobase pairs unless 
indicated otherwise. In particular, the A to G mutation introduced into the unique SwaI site 
in the EcoRI-T fragment of MCMV-ETSwa- is shown in bold at the top of the panel. The 
GFP (green fluorescent protein) cassette inserted into the modified EcoRI-E fragment of 
MCMV-EGFP contains an EF-1 promoter, the coding sequence of GFP, and a SV40 
polyadenylation site. At the bottom of the panel, location of the major immediate-early 
promoter (MIE) is shown along with the bidirectional transcription that resulted in the 
spliced immediate-early transcripts ie1/ie3 and ie2. Thus insertion of the GFP cassette 
disrupts ie2 transcription in MCMV-EGFP. 
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-20°C. Finally, titers of the virus stocks were determined by plaque assays as described in 
section 3.2.2. 
3.3  Bacteria 
3.3.1  Bacterial strains and culture 
Plasmids and Bacterial Artificial Chromosomes (BACs) were maintained in 
Escherichia coli strains DH5? [supE44 lacUl69(80 lacZM15)hsdR17 recA1 endA1 gyrA96 
thi-1 relA1] and DH10B [F- endA1 recA1 galE15 galK16 nupG rpsL ?lacX74 ?80lacZ?M15 
araD139 ?(ara, leu)7697mcrA ?(mrr-hsdRMS-mcrBC)?-], respectively. Both bacterial strains 
were obtained from Invitrogen (formerly Bethesda Research Laboratories, Maryland). 
Homologous recombination between BAC and complementing DNA was carried out in E. coli 
strain DY380 (obtained from Dr. Don Coen of Harvard Medical School) whose genotype is 
DH10B [?cl857 (cro-bioA) <>tet]. The recombination genes exo, bet, and gam in DY380 are 
temperature-sensitive and can be activated at 42°C. 
E. coli strains DH5? and DH10B were grown in Luria Broth (L-Broth) at 37°C with 
vigorous shaking at 200 rotations per minute in an environmental shaker (New Brunswick 
Scientific Co., Inc., Edison, NJ). E. coli strain DY380 was grown at 30°C  in L-Broth 
containing tetracycline (12.5 μg/mL).  When E. coli strain DH5? harbored plasmids 
containing the ampicillin resistance gene, L-Broth was supplemented with ampicillin 
(75 μg/mL).  Similarly, when E. coli strain DH10B harbored a BAC containing a 
chloramphenicol resistance gene, L-Broth was supplemented with chloramphenicol 
(17 μg/mL).  
3.3.2  Preparation of competent cells for electroporation 
For routine preparation of competent bacteria, 500 mL of L-broth was inoculated with 
1/100 volume for an overnight culture of bacteria and incubated at 37˚C with vigorous shaking 
until an OD600 of 0.7 was reached. The bacteria were then chilled on ice for 30 minutes and 
centrifuged at 4000 x g for 15 minutes. The bacteria pellet was resuspended in 500 mL of cold 
distilled water and pelleted again. The washing procedure was repeated 3 times by 
resuspending the bacteria in successively smaller volumes of water. The final pellet was 
resuspended in 2 to 3 mL of cold 10% glycerol and stored at -70˚C in 100 μL aliquots. 
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For homologous recombination in DY380, an overnight culture of the bacteria was 
diluted 1:50 into fresh L-Broth media and the fresh culture was allowed to grow at 30°C until 
an OD600 of 0.5-0.6 was reached. For each recombination reaction, 10 mL of culture was heat 
shocked at 42°C for exactly 15 minutes in a 50-mL Erlenmeyer flask at 200 rpm and quickly 
chilled in an ice water slurry for 10 minutes. The bacteria were pelleted by centrifugation at 
5500 x g for 8 minutes at 4°C and washed 4 times with sterile, deionized water. Finally, 
competent bacteria were resuspended in 100 μL of deionized water and used for 
electroporation within an hour. 
3.4  Cloning vectors and plasmids used in this study 
The cloning vector pTZ18R was purchased from Invitrogen.   All other plasmids used 
in this study were previously constructed in this laboratory and contain MCMV DNA 
fragments cloned into the pTZ18R vector (Table 3.1). 
3.5  DNA purification and analysis 
3.5.1  Small-scale purification of plasmid DNA by the “boiling” method 
The procedure used was adapted from that described in Sambrook et al. (1989). 
Bacteria containing the plasmid of interest were grown in 3 mL of L-Broth supplemented with 
ampicillin (50 μg/ml) at 37°C for 12-16 hours until the stationary phase was reached.  Then 
bacteria were pelleted by centrifugation at 15000 x g for 1 minute in a microfuge and 
resuspended in 350 μL of   STET (0.5 M NaCl, 10 mM Tris-HCl, 1 mM EDTA, 5% (v/v) 
Triton X-100, pH 8.0).  Ten μL of lysozyme (20 mg/mL in STET) was added and the sample 
was boiled for 45 seconds.  The lysed bacteria were then centrifuged at 15000 x g for 8 
minutes at room temperature.  Sixteen μL of 5 M NaCl and 420 μL of isopropanol were added 
to the supernatant.  The solution was incubated for 5 minutes at room temperature before 
plasmid DNA was pelleted by centrifugation at 15000 x g for 15 minutes at room temperature.  
The DNA pellet was washed with 70% ethanol and resuspended in 50 μL of Tris-EDTA buffer 
(TE, 10 mM Tris-HCl and 0.1 mM EDTA, pH 8.0) containing Ribonuclease (RNAse, 
50 μg/mL, Sigma Chemical Co., Missouri).  Purified plasmid DNA was analyzed by 
restriction enzyme digestion and agarose gel electrophoresis as described in section 3.5.5. 
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Table 3.1- Plasmids Used in Recombinant MCMV BAC Construction 
Plasmids listed in this table contain wild-type or modified MCMV EcoRI-E or -T 
fragments cloned into the vector pTZ18R. Restriction maps for these two DNA fragments 
are shown in Figures 4.2, 4.4, and 4.6. Site-directed mutagenesis was used to destroy the 
unique SwaI site in the MCMV genome via an A to G mutation (ATTTAAAT to 
GTTTAAAT), and an unexpected T to A mutation (AATAAA to AAAAAA) was found 
near the SwaI site via nucleotide sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasmid EcoRI 
fragment 
cloned 
Description of the cloned EcoRI fragment 
pTE66 EcoRI-T Wild type sequence containing the unique SwaI site 
pTE77 EcoRI-E Wild type sequence 
pTETSwa- EcoRI-T SwaI site mutation and an unexpected T? A mutation 
pTETSwa-* EcoRI-T SwaI site mutation 
pTETzeo EcoRI-T Zeocin cassette replacing the NotI-BamHI sequences 
pTE-E/SwaZeo EcoRI-E Zeocin cassette replacing the ApaI-HpaI sequences 
 
55 
3.5.2  Large-scale purification of plasmid DNA 
3.5.2.1  Preparation of plasmid DNA by the alkaline lysis method 
This procedure was adapated from that described in Sambrook et al. (1989). Five 
hundred mL of L-Broth supplemented with the appropriate antibiotic was inoculated with 
10 mL of an overnight culture of bacteria harboring the selected plasmid.  The culture was 
allowed to grow at 37°C until the OD600 reached about 0.7, at which point 2.5 mL of 
chloramphenicol (34 mg/mL in ethanol) was added to prevent further bacterial growth, and the 
culture allowed to grow for an additional 12-16 hours.  The bacterial culture was centrifuged at 
2500 x g for 15 minutes and the pellet resuspended in 10 mL of cell suspension buffer (50 mM 
Tris-HCl and 10 mM EDTA, pH 8.0) containing lyzozyme (1 mg/mL).  Ten mL of cell lysis 
solution (0.2 N NaOH, 1% SDS) was then added and the sample incubated at room 
temperature until lysis occurred, at which point 15 mL of neutralization buffer (3.1 M 
potassium acetate, pH 5.5) was added and the mixture allowed to incubate on ice for 10 
minutes.  The bacterial lysate was centrifuged for 20 minutes at 4100 x g and 4°C. Following 
removal of the precipitate, 0.7 x volume of isopropanol was added to the supernatant and the 
solution was centrifuged at 16000 x g for 25 minutes at room temperature. Finally, the DNA 
pellet was washed with 70% ethanol and resuspended in 5 mL TE, pH 8.0. 
3.5.2.2  Purification of plasmid DNA by precipitation with polyethylene glycol 
Plasmid DNA prepared by the alkaline lysis method was further purified by 
precipitation with polyethylene glycol (Sambrook et al., 1989).  Three mL of 5 M LiCl was 
added to the nucleic acid solution obtained in section 3.5.2.1 and centrifuged at 7800 x g for 
10 minutes at 4°C.  The DNA in the supernatant was recovered by the addition of an equal 
volume of isopropanol, incubation for 5 minutes at room temperature, and centrifugation at 
7800 x g for 25 minutes at room temperature.  The crude DNA pellet was washed with 70% 
ethanol and redissolved in 500 μL TE (pH 8.0) containing deoxyribonuclease-free pancreatic 
RNAase (20 μg/ml) and stored at room temperature for 30 minutes. Next, 500 μL of 1.6 M 
NaCl containing 13% (w/v) polyethylene glycol (PEG 8000) was added and the plasmid DNA 
precipitated by centrifugation at 12000 x g for 20 minutes at 4°C.  The pelleted plasmid DNA 
was resuspended in 400 μL of TE (pH 8.0), extracted with phenol-chloroform and then 
chloroform, and precipitated for 10 minutes at room temperature by the addition of 100 μL of 
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10 M ammonium acetate and two volumes of 95% ethanol.  The plasmid DNA was recovered 
by centrifugation at 12000 x g for 20 minutes at 4°C in a microfuge, washed with 70% ethanol, 
and dissolved in 500 μL of TE, pH 8. 
3.5.3  Preparation of Bacterial Artificial Chromosome (BAC) DNA 
A 10 mL culture of bacteria harboring a specific BAC was grown up overnight using 
appropriate temperatures and antibiotics.  If the BAC was harbored in E.coli  DY380, the 
culture was grown at 30°C in L-broth supplemented with tetracycline (12.5 μg/mL) and 
chloramphenicol (17 μg/mL).  However, if the BAC was harbored in E.coli DH10B, the 
culture was grown at 37°C in L-broth supplemented with chloramphenicol. The procedure 
after this point was similar to that given in section 3.5.2.1 with the following modifications. 
First, the bacteria were initially pelleted at 2100 x g and resuspended in 2 mL of cell 
suspension buffer containing 100 μg/mL of RNAse.  Two mL of cell lysis buffer was added, 
and the cleared lysate was centrifuged immediately following the addition of 2 mL of 
neutralization buffer. Secondly, after the BAC DNA was precipitated, it was resuspended in 
50 μL TE, pH 8.0. Finally, all manipulations of BAC DNA were carried out carefully to avoid 
shearing of the large DNA molecules. Purified BAC DNA was analyzed by restriction enzyme 
digestion and agarose gel electrophoresis as described in section 3.5.5. 
3.5.4  Determination of DNA concentration 
The concentration of purified plasmid DNA was determined by measuring the OD260 
and OD280 of an appropriately diluted DNA sample in a UV spectrometer.  An absorbance of 
one at OD260 corresponds to approximately 50 μg/mL of double-stranded DNA.  Thus, the 
plasmid DNA concentration was determined by the following formula: 
Concentration of DNA in μg/mL = dilution factor x 50 μg/mL x OD260 
If the ratio of the absorbance at 260 nm to that at 280 nm is greater than 1.8, the DNA sample 
is considered to be relatively free of contaminating proteins. 
3.5.5  Restriction enzyme digestion and Agarose gel electrophoresis of purified DNA 
Purified plasmid, BAC, or viral DNA was digested with restriction enzymes in 
appropriate buffers supplied by the manufacturers at 37°C for 2 hours.  Following digestion, 
one-tenth volume of a 10X agarose gel-loading buffer (50% (v/v) glycerol, 100 mM EDTA, 
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and 1% (w/v) bromophenol blue) was added to DNA samples prior to separation via agarose 
gel electrophoresis. Typically, 0.7% or 1% agarose (Bio-Rad or Invitrogen) gels were cast in 
either a Horizontal Gel electrophoresis system model H6 (Bethesda Research Laboratories, 
Gaithersburg, MD) or an Easycast Horizontal System Model B1A (OWL, Portsmouth, NH) 
when plasmid DNA was analyzed. BAC or viral DNA samples were separated on 0.7% 
agarose gels on a BRL Horizon 11-14 gel system. Bacteriophage lambda DNA digested with 
EcoRI and Hindlll was used as molecular weight standard markers. DNA fragments were 
separated at 70 volts in 1 X Tris-acetate-EDTA buffer (40 mM Tris-acetate, pH 8.0, and 1 mM 
EDTA, pH 8.3).  Following electrophoresis, gels were stained in distilled deionized water 
containing ethidium bromide (0.1 μg/mL) until bands were readily visible on a Spectroline 
Model TC-302 ultraviolet transillumintaor (Spectronics Corporation, Westbury, NY). Images 
of agarose gel were recorded using the AlphaDigiDoc? system from Alpha Innotech. 
3.6  Construction of bacterial artificial chromosomes containing the MCMV genome by 
homologous recombination in DY380 cells 
3.6.1  Purification of DNA fragments from agarose gels 
Plasmid DNA was digested with suitable restriction enzymes. The desired DNA 
fragment was separated from the cloned vector by agarose gel electrophoresis and DNA was 
visualized as described in section 3.5.5.  The DNA fragment was then excised from the 
agarose gel and purified using the GENECLEAN II Kit (BIO 101 Inc., La Jolla, CA) 
according to the manufacturer’s instructions.  Briefly, NaI (3 x w/v) was added the excised gel 
bands and the agarose was melted at 49°C for 5 minutes.  Ten μL of GLASSMILK? was 
incubated with the DNA sample for 10 minutes at room temperature. The 
GLASSMILK?/DNA complexes were pelleted by brief centrifugation at 15000 x g at room 
temperature and washed with 1 mL of NEW WASH? Buffer 4 times.  The pellet was allowed 
to dry for 5 minutes prior to resuspension in 5 to 10 μL of TE and elution at 49°C for 5 to 6 
minutes. The purified DNA was recovered by centrifugation at 15000 x g for 20 seconds at 
room temperature to remove the precipitated GLASSMILK?. If it was necessary, the DNA 
was precipitated in 75% ethanol and resuspended in a volume suitable for a specific 
experiment. 
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3.6.2  Preparation of linear BAC DNA 
Parental BAC DNA containing a zeocin cassette was purified as described in section 
3.5.3 and digested with SwaI (New England Biolabs) for 2 hours at 25°C.  Next, the restriction 
enzyme and residual protein contaminants were removed by phenol-chloroform extraction and 
the linearized DNA was precipitated in 0.2 M NaCl and 70% ethanol. Finally, the purified 
BAC DNA was resuspended in TE buffer containing the DNA fragment targeted for 
homologous recombination. 
3.6.3  Transformation of DNA into competent cells and screening of BAC recombinants 
Electroporation was performed using a Bio-Rad Gene pulser set at 25 μFD, 200 ?, and 
2.5 kilovolts according to the manufacturer’s instructions.  When we were replacing a zeocin 
cassette with a complementing DNA fragment, 1 μL of BAC DNA from section 3.6.2 was 
mixed with 40 μL of competent DY380 bacteria and added to a gene pulser cuvette. When we 
were inserting a zeocin cassette into the MCMV genome, 1 μL of a gel-purified DNA 
fragment containing the cassette was added to competent DY380 bacteria that harbored the 
MCMV BAC. Following successful electroporation, 0.5 mL of SOC media (2% (w/v) bacto-
tryptone, 0.5% (w/v) bacto-yeast extract, 0.05% (w/v) NaCl, and 20 mM glucose) was added 
to the transformed cells and the bacteria were allowed to recover at 30°C for 2 hours with 
gentle shaking. In cases where we were screening for zeocin sensitivity (loss of zeocin 
cassette), bacteria were spread on L-broth plates supplemented with chloramphenicol 
(17 μg/mL) and incubated at 30°C until colonies were clearly visible. These colonies were 
replica plated on L-broth plates supplemented with either chloramphenicol alone or 
chloramphenicol and zeocin and grown at 30°C.  For homologous recombination of BAC 
DNA involving the insertion of a zeocin cassette into the MCMV genome, bacteria were 
plated on L-broth plates supplemented with chloramphenicol and zeocin (25 μg/mL). 
Subsequently, selected colonies were grown up in liquid culture containing appropriate 
antibiotics and BAC DNA was purified from these bacteria for analysis by restriction enzyme 
digestion and agarose gel electrophoresis as described in sections 3.5.3 and 3.5.5. Finally, 
bacteria harboring BAC DNA with the correct profiles were frozen at -70°C and BAC DNA 
from these colonies was transformed into competent DH10B bacteria for stable, long-term 
maintenance of BAC clones. 
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3.7  Rescue of recombinant virus in tissue culture 
3.7.1  Purification of MCMV BAC DNA using the CONCERT high purity plasmid 
purification system 
The Concert high purity plasmid purification system (Invitrogen) was used to purify 
MCMV BAC DNA to obtain DNA of sufficient purity for transfection. The initial steps were 
similar to those described in section 3.5.3. Bacteria harboring MCMV BACs were grown 
overnight in 10 mL of L-broth containing appropriate antibiotics.  Bacteria were centrifuged at 
9000 x g  for 15 min and the pellet was resuspended in 2 mL of cell suspension buffer 
containing RNAse A (400 μg/mL).  Resuspended cells were lysed for 5 minutes at room 
temperature by adding 2 mL of cell lysis solution.  Two mL of neutralization buffer were 
added to the lysed bacteria and the mixture was centrifuged at 15000 x g for 10 minutes at 
room temperature. The supernatant was removed and added to a DNA-purification column that 
was previously equilibrated with equilibration buffer (600 mM NaCl, 100 mM sodium acetate, 
0.5% (v/v) TritonX-100, pH 8.0). Subsequently, the column was washed with 2.5 mL of wash 
buffer (0.9 mM NaCl, 100 mM sodium acetate, pH 5.0) and BAC DNA was eluted from the 
column with 0.9 mL of elution buffer (1.25 mM NaCl, 100 mM Tris-HCl, pH 8.5) pre-warmed 
to 49˚C.  Eluted DNA was precipitated by adding 0.7 x volumes of isopropanol and 
precipitated at 12000 x g for 30 minutes at 4°C.  The DNA pellet was washed with 75% 
ethanol, centrifuged at 15000 x g at 4°C for 5 minutes, dried in air for 5 minutes, and dissolved 
in 25 μL of TE, pH 8.0. 
3.7.2  Transfection of Balb/3T3 cells with MCMV BAC DNA 
Balb/3T3 cells were transfected with purified BAC DNA using LipofectAMINE PLUS 
Reagent (Invitrogen) according to the manufacturer’s instructions. Briefly, Balb/3T3 cells 
which were 70% confluent in 35 mm plates were washed and incubated in 0.8 mL of DMEM 
prior to transfection. Purified MCMV BAC DNA (section 3.7.1) was diluted into 100 μL of 
DMEM to maintain an appropriate concentration for transfection. Six μL of PLUS Reagent 
was added to the diluted DNA mixture and incubated at room temperature for 15 minutes. One 
hundred microliters of DMEM supplemented with 4 μL of LipofectAMINE reagent was added 
to the DNA/PLUS Reagent mixture and incubated at room temperature for a further 15 
minutes. The DNA/PLUS reagent/LipofectAMINE complexes were then added to the cells 
prior to a 3-hour incubation at 37°C. Finally, 1 mL of DMEM supplemented with 10% FCS 
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was added to each plate and cells were allowed to recover overnight.  Media were changed the 
next day and then once every 3 days. 
Transfected cells were monitored everyday for signs of viral infection. Once foci of 
infection were present (usually 1-2 weeks post-transfection), media containing released virus 
particles were collected. Virus contained in the supernatant was subjected to 3 rounds of 
plaque-purification and at least two independently isolated virus clones from each transfection 
were kept for further experimentation. High titer virus stocks were produced for 
experimentation as described in section 3.2.4. 
3.7.3  Isolation of viral DNA from infected cells 
3T3-L1 cells in 60 mm plates were infected with recombinant MCMV at a MOI of one. 
Once most of the cells were in the late phases of infection, media were removed, and cells 
were rinsed 2-3 times with phosphate-buffered saline (PBS, 0.8% (w/v) NaCl, 0.02% (w/v) 
KCl, 0.02% (w/v) KH2PO4, 0.22% (w/v) Na2HPO4
.7H2O, pH 7.4).  Cells were then lysed in 
1 mL of buffer A (0.6% (w/v) SDS, 10 mM EDTA, pH 7.5) supplemented with 0.66 mL of 
5 M NaCl and the plate was incubated at 4°C overnight. Next, cellular DNA and proteins were 
precipitated by centrifugation at 15000 x g for 30 minutes at 4°C and the supernatant was 
extracted with phenol-chloroform and then chloroform.  Once extraction was complete, 2.5 x 
volumes of 95% ethanol was added and viral DNA was pelleted by centrifugation at 15000 x g 
for 20 minutes at 4°C.  The DNA pellet was washed with 70% ethanol and dissolved in 100 
μL of TE, pH 8.0. Purified viral DNA was analyzed by restriction enzyme digestion and 
agarose gel electrophoresis. 
3.8  Analysis of MCMV proteins 
3.8.1  Antibodies 
All monoclonal antibodies were generated in our laboratory previously. Monoclonal 
antibody 9D3.22A is specific for M112-113 (E1) gene products with molecular weights of 
33 kDa, 36 kDa, 38 kDa, and 87 kDa (Loh et al., 1991). Monoclonal antibody 3B9.22A 
recognizes the early-late protein pp50 (50 kDa) encoded by M44 (Loh et al., 1991). 
Monoclonal antibody 2E8.12A is specific for the envelope glycoprotein gB (Loh et al., 1988). 
It recognizes an epitope present on the 128 kDa gB precursor, the 150 kDa uncleaved form of 
gB, and the 100 kDa subunit of the gB glycoprotein. 
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3.8.2  Preparation of whole cell extracts 
Cells grown in a 35 mm plate were infected at a MOI of 5 with MCMV (Smith strain) 
or recombinant MCMV when they were 60% confluent.  At each time point, cells were 
washed 3 times with cold PBS and solubilized in 0.35 mL of radioimmunoprecipitation assay 
buffer (RIPA, 50 mM Tris-HCl, 150 mM NaCl, 1% (v/v) NP-40, 0.5% (w/v) deoxycholate, 
and 0.1% (w/v) SDS, pH 8.0) for 1 hour on ice.  Soluble proteins were collected following 
centrifugation at 12000 x g for 15 minutes at 4°C and analyzed by western blot as described in 
section 3.8.4. 
3.8.3  Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed as 
described by Laemmli (1970).    Protein samples solubilized in SDS-PAGE sample buffer 
(50 mM Tris-HCl, 5% (v/v) 2-mercaptoethanol, 2% (w/v) SDS, 10% (v/v) glycerol, 0.1% 
(w/v) bromophenol blue, pH 6.8) were heated at 100°C for 5 minutes and analyzed on either 
7.5% or 9% polyacrylamide gels in a mini-PROTEIN II electrophoresis cell (Bio-Rad).  Pre-
stained molecular weight standards (Bio-Rad) were used to determine the sizes of protein 
bands. Gels were run at 100 volts in Tris-glycine electrophoresis buffer (10% (v/v) 10x Tris-
glycine buffer, 0.1% (w/v) SDS, pH 8.3) until the dye front migrated to within 1 cm of the 
bottom edge of the gel. 
3.8.4  Western blotting analysis 
Following SDS-PAGE, proteins were transferred to a nitrocellulose membrane (Bio-
Rad, Canada) electrophoretically in transfer buffer (10% (v/v) 10x Tris-glycine buffer, 20% 
(v/v) methanol, 70% (v/v) ddH2O) at 100 volts for two hours as described by Towbin et al. 
(1979). The membrane was blocked overnight in Tris-buffered saline (TBS, 50 mM Tris base 
and 150 mM NaCl, pH 7.4) containing 1% Bovine Serum Albumin (blocking buffer). Next, 
the nitrocellulose membrane was incubated for three hours with an appropriate dilution of a 
specific monoclonal antibody in blocking buffer. Following three washes in TBS containing 
0.05% (v/v) Tween 20 (TBST), the membrane was incubated for one hour with alkaline 
phosphatase conjugated goat anti-mouse antibody (BioRad) at a 1:3000 dilution.  
Subsequently, the membrane was washed 4 times in TBST and once with TBS before 10 mL 
of alkaline phosphatase buffer (0.1 M Tris-HCl, 0.1 M NaCl, and 50 mM MgCl2, pH 9.5) 
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containing 44 μL of p-nitro blue tetrazolium chloride (NBT) and 33 μL of 5-bromo-4-chloro-
3-indoyl phosphate p-toluidine salt (BCIP) were added to allow the visualization of protein 
bands reactive with the monoclonal antibody. The reaction was stopped by washing the 
membrane in ddH2O. 
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4.0  RESULTS 
4.1  Development of a modified protocol to produce recombinant virus 
4.1.1  Rationale and strategy for recombinant MCMV construction using a modified 
MCMV genome 
Our laboratory has made use of the fact that bacteria can be transformed more 
efficiently by circular rather than linear plasmids to develop a modified method for BAC 
mutagenesis and recombinant virus production. The protocol depends on the introduction of 
unique restriction sites into the viral genome so that the BAC containing the entire MCMV 
genome can be linearized at the region targeted for mutagenesis. Subsequent homologous 
recombination with a viral DNA fragment containing the desired mutation allows re-
circularization of the BAC and efficient transformation of the host bacteria. Because of the 
size of the MCMV genome, we were unable to find a restriction site that is absent from 
pMCMV-EGFP, the BAC containing the entire viral genome (originally obtained from Dr. Jay 
Nelson, Oregon Health Sciences University). However, a unique SwaI site is present in a 
region of the MCMV genome (EcoRI-T fragment) that does not appear to contain predicted 
open reading frames of significant sizes (<300 bp). Therefore, the unique SwaI site was 
destroyed by site-directed mutagenesis (ATTTAAAT to GTTTAAAT, Figure 3.1) and the 
resulting BAC (pMCMV-ETSwa-) was used as the “backbone” for the construction of 
recombinant viruses.  Although the SwaI site is within a 63 bp open reading frame located 
between m119 and m119.1 in the MCMV genome (Rawlinson et al., 1996), the mutation 
introduced did not alter the amino acid sequence of the short ORF. Nevertheless, the effect of 
the SwaI mutation on MCMV growth properties needs to be tested experimentally to ensure 
that any as yet uncharacterized control sequence, intron, or exon is not affected. It should be 
noted that the SwaI site can easily be restored using the same mutagenesis procedure 
mentioned above after all the desired mutations have been introduced into the genome. 
As shown in Figure 4.1, our modified BAC construction protocol began with the 
homologous recombination between a MCMV BAC and a zeocin (zeo) cassette flanked by 
two SwaI sites and homologous viral sequences.  This resulted in the insertion of the zeocin 
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cassette into a region of the MCMV genome (lacking SwaI site) that we wished to manipulate. 
Correct recombinants were isolated as zeocin-resistant clones and analyzed by restriction 
endonuclease digestion. Then the MCMV BAC was linearized by digestion with SwaI, 
resulting in the excision of the zeocin cassette. The linearized BAC and a viral DNA fragment 
containing the desired mutation were transformed into recombination-competent bacteria 
where homologous recombination could take place. The loss of zeocin resistance was selected 
for by replica plating and potentially correct recombinants were screened by restriction 
endonuclease analysis. Then DNA from BAC clones with the expected restriction profiles 
were transfected into mammalian cells and recombinant virus were recovered, assuming that 
the mutation did not affect the viability of the virus. 
The original pMCMV_EGFP BAC from Dr. Jay Nelson contained a GFP cassette 
(coding sequence of the green fluorescence protein) inserted within the MIE region of the 
genome (Figures 3.1 and 4.2). This insertion resulted in the disruption of murine ie2 gene 
expression. Although mie2 is dispensable for MCMV replication, MCMV-EGFP appeared to 
have a reduced capacity to replicate in COS-1 cells (unpublished results in our laboratory), 
suggesting that mie2 may play a role in host specificity.  Therefore, we made an initial attempt 
to test this hypothesis by replacing the GFP cassette with wild-type EcoRI-E sequences 
through homologous recombination using our modified BAC construction method. 
To determine whether the biological properties of MCMV are affected by the 
destruction of the SwaI site or the presence of the GFP cassette, the growth properties of 
MCMV_ETSwa- or MCMV-EGFP need to be compared to the Smith strain of MCMV and 
MCMV-ETwt where the SwaI site has been restored and the GFP cassette replaced with wild-
type sequences (Figure 3.1). For example, if recombinant MCMV containing the SwaI 
mutation were to behave the same way as their parental counterparts, it would suggest that 
additional steps to restore the SwaI site might not be necessary. 
4.1.2  Construction of recombinant viruses 
The list of BACs relevant to this thesis is shown in Figure 4.3 and Table 4.1. Prior to 
my involvement in this project, pMCMV_EGFP BAC has been modified by the insertion of a 
zeocin cassette into the EcoRI-T region, creating pMCMV_EGFP_ETzeo. The zeocin cassette 
was then replaced with a modified EcoRI-T region containing a SwaI- mutation (Figure 4.2), 
resulting in pMCMV_EGFP_ETSwa-. Part of the MIE region of the EcoRI-E fragment of 
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Table 4.1  Descriptions of MCMV BACs 
 
MCMV BAC EcoRI 
fragments 
modified 
Description of the modifications 
pMCMV_EGFP EcoRI-E GFP cassette inserted between the 2 HpaI sites 
pMCMV_EGFP_ETzeo EcoRI-E  
 
EcoRI -T 
GFP cassette inserted between the 2 HpaI sites 
in the EcoRI-E fragment 
Zeocin cassette replacing the NotI-BamHI 
fragment of the EcoRI-T fragment 
pMCMV_EGFP_ETSwa- EcoRI-E  
 
EcoRI -T 
GFP cassette inserted between the 2 HpaI sites 
in the EcoRI-E fragment 
SwaI mutation and an unexpected T? A 
mutation in the EcoRI-T fragment 
pMCMV_ETSwa-/MIESwaZeo EcoRI-E  
 
EcoRI -T 
Zeocin cassette replacing the ApaI-HpaI 
fragment in the EcoRI-E fragment 
SwaI mutation and an unexpected T? A 
mutation in the EcoRI-T fragment 
pMCMV_ETSwa- EcoRI-T SwaI mutation and an unexpected T? A 
mutation in the EcoRI-T fragment  
pMCMV_ETSwaZeo EcoRI-T Zeocin cassette replacing the NotI-BamHI 
fragment 
pMCMV_ETSwa-* EcoRI-T SwaI mutation 
pMCMV_ETwt EcoRI-T Wild type sequences 
pMCMV_ETSwa–*/ie1SwaZeo EcoRI-E 
 
EcoRI-T 
Zeocin cassette replacing the ApaI-HpaI 
fragment in the EcoRI-E fragment 
SwaI mutation in the EcoRI-T fragment 
 
This table lists the names of the MCMV BACs relevant to this study, the EcoRI fragment that 
was modified in a particular BAC, and a brief description of the specific modifications. 
Restriction maps of the EcoRI-E and -T fragments are shown in Figures 4.2, 4.4, and 4.6. Site-
directed mutagenesis was used to destroy the unique SwaI site (ATTTAAAT to GTTTAAAT), 
whereas the unexpected T to A mutation occurred in a nearby sequence (AATAAA to 
AAAAAA). 
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pMCMV_EGFP_ETSwa- was then replaced with a zeocin cassette to yield pMCMV_ETSwa-
/MIESwaZeo. 
4.1.2.1  Construction of pMCMV_ETSwa
-
 
The purpose of inserting a zeocin cassette into the MIE region was to replace the 
modified EcoRI-E, which contained a GFP cassette, with wild-type sequences. This was 
accomplished by homologous recombination between pMCMV_ETSwa-/MIESwaZeo, which 
was linearized by digestion with SwaI, and the EcoRI-E fragment excised from pTE77 
according to protocols described in section 3.6. The GFP cassette was inserted within the MIE 
region of the MCMV EcoRI-E fragment, causing a 1.5 kb insertion in this fragment as well as 
the HindIII-L fragment which is part of this region (Figure 4.2 and Figure 4.4 panel B). 
Replacement of the zeocin cassette with the wild-type EcoRI-T fragment, and thus removal of 
the GFP cassette, should result in a decrease in the size of the EcoRI-E fragment from 14.1 kb 
to 12.7 kb, and a decrease in the size of the HindIII-L fragment from 8.56 kb to 7.16 kb 
(Figure 4.4, panels A and B). Following selection, replica plating and restriction analysis, two 
zeocin-sensitive colonies (Table 4.2) yielded the expected restriction profile for 
pMCMV_ETSwa- (Figure 4.5). Differences in the EcoRI restriction profiles were not readily 
apparent on the gel (Figure 4.5, Lanes 4-6) due to the reduced resolution of fragment sizes at 
that range of molecular weights. However, more obvious differences were demonstrated by 
digestion with HindIII, where the expected changes in the restriction profiles were observed 
(Figure 4.5, Lanes 1-3). 
4.1.2.2 Construction of pMCMV_ETSwaZeo_1 
Once pMCMV_ETSwa- was constructed, nucleotide sequencing revealed an 
unexpected AATAAA to AAAAAA mutation in the modified EcoRI-T fragment that might 
affect properties of the virus by altering a putative polyadenylation signal. Therefore, we 
decided to remove this point mutation. The first step involved the replacement of the 1.32 kb 
NotI-BamHI fragment (Figures 4.2 and 4.6) in the EcoRI-T region of the genome with a zeocin 
cassette. Homologous recombination between the EcoRI-T fragment from pTETzeo (Table 
3.1) and pMCMV_ETSwa- resulted in the BAC pMCMV_ETSwaZeo_1. This construct should 
contain a modified 3.67 kb EcoRI-T fragment that replaced the 4.54 kb EcoRI-T fragment 
from pMCMV_EGFP_ETSwa- (Figure 4.2 and Figure 4.6, panels B and C). Insertion of 
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the zeocin cassette also resulted in the fusion of the 22.4 kb HindIII-F and 7.56 kb HindIII-K 
fragments, creating a 30.0 kb fragment via the removal of the HindIII site between these 
fragments (Figure 4.2, and Figure 4.6, panel B). All 4 zeocin resistant clones tested showed the 
expected restriction profile for pMCMV_ETSwaZeo_1 (Figure 4.7, and Table 4.2). After 
digestion with EcoRI, the 4.54 kb EcoRI-T fragment was lost (reduced intensity of the 4.54 kb 
DNA band in Figure 4.7, lanes 5 and 7, compared to the 4.54 kb band representing 2 co-
migrating fragments in lane 6) and a 3.67 kb fragment appeared (Figure 4.7, lanes 5 and 7). In 
addition, the 7.56 kb HindIII-K fragment was replaced with the expected 30.0 kb fragment 
(cannot be resolved adequately from other high molecular weight DNA fragments of similar 
sizes on a 0.7 % gel) after digestion of pMCMV_ETSwaZeo_1 DNA with HindIII (arrow in 
Figure 4.7, lanes 1 and 3; Figure 4.6, panels B and C). 
4.1.2.3  Construction of pMCMV_ETSwa-*_1 
Once we had successfully inserted the zeocin cassette into the EcoRI-T region of the 
MCMV genome, we wanted to replace the zeocin cassette with the modified 1.32 kb NotI-
BamH1 sequence containing the correct SwaI mutation. The BAC pMCMV_ETSwaZeo_1 was 
digested with SwaI to remove the zeocin cassette and co-transformed with the modified 
EcoRI-T fragment from pTETSwa-* (Table 3.1) into the DY380 strain of E. coli to yield 
pMCMV_ETSwa-*_1. The loss of the zeocin cassette and the incorporation of the SwaI 
mutation should result in a 4.54 kb EcoRI-T region and the restoration of the HindIII-F/K site 
(Figure 4.6, panel C). Following selection, replica plating, and restriction analysis, two zeocin 
sensitive clones had the expected restriction profile for pMCMV_ETSwa-*_1 (Table 4.2). 
After digestion with EcoRI/SwaI, the 2.67 kb band was lost, and a 4.54 kb fragment appeared, 
resulting in a more intense DNA band at that position (arrows in Figure 4.8, lanes 1 and 2; 
Figure 4.6, panels B and C). The 0.45 kb and 0.55 kb bands were probably too faint to be seen 
at the bottom of the gel. In addition, digestion of pMCMV_ETSwa-*_1 with HindIII resulted 
in the appearance of a 7.56 kb fragment not present during digestion of 
pMCMV_ETSwaZeo_1 (arrows in Figure 4.8, lanes 6 and 7). 
4.1.2.4  Reconstruction of pMCMV_ETSwaZeo (pMCMV_ETSwaZeo_2) 
Although we had previously constructed the two BACs pMCMV_ETwt_1 and 
pMCMV_ETSwa-*_1, initial isolations of pMCMV_ETwt_1 from pMCMV_ETSwaZeo_1 
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Table 4.2  Analysis of MCMV BAC clones 
 
MCMV BAC 
Total 
number of 
zeocin 
sensitive 
clones 
Number 
of clones 
tested 
Number of 
clones with 
correct 
profiles 
% of tested 
clones with  
correct profiles 
pMCMV_ETSwaZeo_1 ND 4 4 100% 
pMCMV_ETSwa- 66 15 (23%) 4 27% 
pMCMV_ETwt_1 32 4 (13%) 1 25% 
pMCMV_ETSwa-*_1 73 23 (32%) 2 8.7% 
pMCMV_ETSwaZeo_2 ND 4 4 100% 
pMCMV_ETwt_2 75 17 (23%) 5 29% 
pMCMV_ETSwa-*_2 145  8 (5.5%) 2 25% 
pMCMV_ETSwa-*/ie1SwaZeo ND 4 4 100% 
 
This table provides a summary of the data from my analysis of MCMV BAC clones relevant 
to this thesis. Briefly, zeocin sensitive or resistant MCMV BAC clones were isolated by 
replica plating and BAC DNA from these clones were tested for the expected profile by 
restriction analysis. When a zeocin cassette was inserted into a BAC (pMCMV_ETSwaZeo_1, 
pMCMV_ETSwaZeo_2, and pMCMV_ETSwa-*/ie1SwaZeo), the total number of zeocin 
resistant clones were not determined (ND) since these numbers were typically quite large, and 
every clone tested was shown to possess the correct restriction profile. In addition, only a 
percentage of the zeocin sensitive clones were analyzed (shown inside brackets in column 3). 
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(marked with ** in Figure 4.3) were very inefficient and inevitably resulted in the production 
of at most one correct clone per experiment. This was a concern as multiple clones with the 
correct profiles were generally obtained for all other recombinants constructed in this 
laboratory (Table 4.2 and unpublished results). Moreover, our observation that growth 
properties of recombinant MCMVs derived from these pMCMV_ETwt clones were not 
comparable to wild-type MCMV (data not shown) led us to believe that these BACs might 
contain genomic alterations that were not readily detectable through restriction analysis. 
Multiple attempts to construct correct pMCMV_ETwt clones from pMCMV_ETSwaZeo_1 
clone 1.4 yielded similarly disappointing results, suggesting that perhaps the mutation resided 
in this particular construct. However, virus rescued from pMCMV_ETSwa-*_1 clone 1.16 
appeared to replicate normally in tissue culture. Therefore, we decided to use this BAC as a 
starting point to reconstruct pMCMV_ETwt (pMCMV_ETwt_2 in Figure 4.3). 
First, the 4.54 kb EcoRI-T fragment in pMCMV_ETSwa-*_1 clone 1.16 BAC was 
replaced with the 3.67 kb modified EcoRI-T fragment in the pTETzeo (Table 3.1; Figure 4.6, 
panels B and C). All four zeocin resistant clones tested had the expected profile for 
pMCMV_ETSwaZeo (Table 4.2). These BACs were designated pMCMV_ETSwaZeo_2. As 
shown in Figure 4.9, after digestion of pMCMV_ETSwaZeo_2 with EcoRI, one 4.54 kb 
fragment was lost (reduced intensity of the 4.54 kb band in lane 5 compared to the 4.54 kb 
band representing 2 co-migrating fragments in lane 4) and a new 3.67 kb fragment appeared 
(lane 5). Digestion with EcoRI and SwaI resulted in three bands from the EcoRI-T region of 
pMCMV_ETSwaZeo_2 (2.67 kb, as well as 0.45 kb and 0.55 kb bands which have probably 
run off the gel) in contrast to the 4.54 kb band representing the EcoRI-T region of 
pMCMV_ETswa-*_1 clone 1.16 (Figure 4.9, lanes 1 and 2; Figure 4.6, panels B and C). 
4.1.2.5  Reconstruction of pMCMV_ETwt (pMCMV_ETwt_2) 
The pMCMV_ETSwaZeo_2 clone 2.4 BAC was used to reconstruct pMCMV_ETwt, a 
BAC that should contain “wild-type” MCMV sequences identical to the Smith strain of 
MCMV. To accomplish this, pMCMV_ETSwaZeo_2 was digested with SwaI and co-
transformed into the DY380 strain of E. coli with the EcoRI-T fragment from pTE66 (Table 
3.1) under conditions that promoted homologous recombination. Following replica plating and 
restriction analysis, five of the zeocin-sensitive colonies (Table 4.2) had the expected 
restriction profile for pMCMV_ETwt_2 (Figures 4.10 and 4.11). As expected (Figure 4.6, 
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panels A and B), digestion of pMCMV_ETwt_2 with EcoRI and SwaI resulted in the 
appearance of 2.75 kb and 1.79 kb bands (Figure 4.10, lanes 5-9) that were not present in 
pMCMV_ETSwaZeo_2 (Figure 4.10, lane 3). Moreover, the HindIII-F/K site should be 
restored in pMCMV_ETwt_2 (Figure 4.6, panels A and B). Thus digestion of 
pMCMV_ETwt_2 with HindIII resulted in the appearance of a 7.56 kb band (arrow in Figure 
4.11, lanes 5-9) that was absent in pMCMV_ETSwaZeo_2 (Figure 4.11, lane 3). This was a 
vast improvement over previous attempts at constructing pMCMV_ETwt where only one 
recombinant had the expected restriction profile. 
4.1.2.6  Reconstruction of pMCMV_ETSwa
-
* (pMCMV_ETSwa
-
*_2) 
The BAC pMCMV_ETSwaZeo_2 was used to construct pMCMV_ETSwa-*_2 so that 
it shared the same genetic background as pMCMV_ETwt_2 other than the SwaI mutation. The 
pMCMV_ETSwaZeo_2 BAC (clone 2.4) was digested with SwaI to remove the zeocin 
cassette and co-transformed with the modified EcoRI-T fragment from pTETSwa-* (Table 3.1) 
into the DY380 strain of E. coli. Following selection, replica plating, and restriction analysis, 
two zeocin sensitive clones (Table 4.2) had the expected EcoRI/SwaI and HindIII restriction 
profiles for pMCMV_ETSwa-*_2 (Figure 4.6, panels B and C). The loss of the zeocin cassette 
and the presence of the SwaI mutation should result in the appearance of a 4.54 kb fragment 
and the disappearance of the 2.67 kb fragment from this region following digestion of 
pMCMV_ ETSwa-*_2 with EcoRI and SwaI (Figure 4.10, lanes 1 and 2). In addition, 
restoration of the HindIII-F/K site in pMCMV_ETSwa-*_2 should result in the appearance of 
a 7.56 kb HindIII-K fragment (arrow in Figure 4.11, lanes 1 and 2). This BAC will be used as 
the “backbone” for the construction of MCMV mutants in the future using the protocol 
described in this thesis. 
4.1.2.7  Construction of pMCMV_ETSwa
-
*/ie1SwaZeo 
As a first step towards constructing MCMV mie1 mutants that could be useful for 
studying CMV host specificity, we replaced the 3.3 kb HpaI-ApaI segment of the wild-type 
EcoRI-E fragment in pMCMV_ETSwa-*_2 with the zeocin cassette from pTE-E/SwaZeo to 
create pMCMV_ETSwa-*/ie1SwaZeo. The changes made to the EcoRI-E fragment could be 
seen in Figure 4.4 (panels A and C). Experimentally, this was accomplished via homologous 
recombination between the modified EcoRI-E fragment from pTE-E/SwaZeo and 
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pMCMV_ETSwa-*_2 in DY380 cells as described in section 3.6. All four zeocin-resistant 
clones selected for BAC DNA purification and analysis showed the expected restriction profile 
for pMCMV_ETSwa-*/ie1SwaZeo. As shown in Figure 4.4 (panels A and C), digestion of 
pMCMV_ETSwa-*/ie1SwaZeo with EcoRI/SwaI resulted in the appearance of bands of 
5.35 kb, 4.01 kb and 0.45 kb, and the disappearance of a 12.7 kb band (Figure 4.12, lanes 1-5). 
On the other hand, digestion of pMCMV_ETSwa-*/ie1SwaZeo with HindIII resulted in the 
disappearance of the 7.16 kb HindIII-L fragment, and the appearance of a 4.3 kb band (Figure 
4.12, lanes 7-11) when the 3.3 kb HpaI-ApaI fragment was replaced with the 0.45 kb zeocin 
cassette (Figure 4.4, panels A and C). In the future, the pMCMV_ETSwa-*/ie1SwaZeo BAC 
would be used for the construction of specific MCMV mie1 mutants by replacing the zeocin 
cassette with viral DNA fragments containing defined mutations or alterations of the MCMV 
mie1 gene via the homologous recombination methodology described in this thesis. 
4.2  Characterization of Recombinant Viruses 
Recombinant MCMVs were recovered from Balb/3T3 fibroblasts transfected with 
MCMV BACs as described in section 3.7, and recombinant viruses that are relevant to the 
studies described in this thesis are listed in Table 4.3. 
4.2.1  Analysis of recombinant Viral DNA restriction patterns 
Although the restriction profiles for pMCMV_EGFP, pMCMV_ETwt_2 and 
pMCMV_ETSwa-*_2 were correct (section 4.1.2), we needed to ascertain that viral DNA 
purified from MCMV-EGFP, MCMV-ETwt, and MCMV-ETSwa- showed the expected 
restriction profiles. To this end, permissive Balb/3T3 fibroblasts were infected with these 
recombinant viruses as well as the Smith strain of MCMV, and viral DNA was purified from 
infected cells during the late phase of the replication cycle. The DNA was analyzed by 
digestion with either EcoRI/SwaI or HindIII and the results are shown in Figure 4.13. As 
predicted in Figure 4.6 (panels A and C), the major observable difference between MCMV-
ETSwa- and the other 3 viruses lied in the EcoRI-T fragment. The MCMV (Smith), MCMV-
EGFP, and MCMV-ETwt viruses should show very similar restriction profiles, with the 
EcoRI-T fragment being cleaved into 2.75 kb and 1.79 kb fragments during digestion with 
EcoRI/SwaI, whereas in MCMV-ETSwa-, with the destruction of the SwaI site, the intact 
4.54 kb EcoRI-T fragment would be seen. Although the insertion of the GFP cassette in 
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Table 4.3  Production of recombinant MCMV stocks 
 
Virus stock MCMV BAC DNA 
MCMV_ETSwa- pMCMV_ETSwa-*_2 
MCMV_ETwt pMCMV_ETwt_2 
MCMV_EGFP pMCMV_EGFP 
Each of the recombinant MCMVs listed on the left hand column was recovered from Balb/3T3 
fibroblasts transfected with DNA purified from the MCMV BAC listed in the column 
immediately to its right using protocols described in section 3.7. 
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MCMV-EGFP produced a slightly larger EcoRI-E fragment (14.1 kb versus 12.7 kb), the 
difference would not be obvious on a 0.7% agarose gel. This was exactly what was observed 
in Figure 4.13 (lanes 1-4). It was noted that the DNA fragments from MCMV (Smith strain) 
were not particularly well resolved even though they were all present (lane 4). In contrast, 
MCMV-EGFP was most easily distinguishable from the other 3 viruses by its HindIII 
restriction profile (predicted in Figure 4.4, panels A and B). As shown in Figure 4.13 (panels 
6-9), the modified HindIII-L fragment of MCMV-EGFP, with the insertion of the GFP 
cassette, was 8.56 kb, whereas the unaltered fragments from the other 3 viruses were 7.16 kb. 
Therefore it is likely that no major genome rearrangements have occurred in the recombinant 
viruses rescued from cells transfected with the 3 selected MCMV BACs based on the 
restriction analyses performed here. 
4.2.2  Expression of representative MCMV genes 
I then proceeded to explore whether there were differences exhibited in the progress of 
these recombinant viruses through their life cycles. The time course and level of expression of 
viral proteins belonging to different kinetic classes during MCMV infection was monitored 
and no significant differences between MCMV (Smith strain), MCMV-EGFP, and MCMV-
ETSwa- (Figure 4.14) were found. For example, the M112-113 proteins were already highly 
expressed at 7 hours post-infection (panel A) and persisted throughout the infection. The major 
gene products with sizes of 36 kDa and 38 kDa were readily detectable in infected cells, 
whereas bands representing the 33 kDa and 87 kDa proteins were faint, but still visible. 
Meanwhile, ppM44, a delayed early protein was barely detectable at 12 hours post-infection, 
but expressed at high levels only after DNA replication had commenced (panel B). Finally, the 
128 kDa gB precursor, the most abundant form of the glycoprotein in infected cells, was 
faintly detectable during the late phase of infection (panel C). Thus, the level of accumulation 
of viral proteins in infected cells did not differ significantly between the different MCMV 
recombinants, indicating that neither the SwaI mutation nor the presence of the GFP insertion 
affected the expression of viral proteins belonging to different kinetic classes. In addition, the 
coding sequences for the viral proteins monitored in this experiment are located in different 
parts of the viral genome. Therefore, my results provided additional support for the absence of 
aberrant genome rearrangements during the construction of MCMV mutants. 
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Figure 4.14:  Expression of viral proteins during infection by recombinant murine 
cytomegaloviruses  
Balb/3T3 fibroblasts infected by recombinant MCMV (MOI = 5) were harvested at 2, 7, 12, 
and 24 hours post-infection (Hrs p.i.) and processed for Western blotting. The viral gene 
products M112-113 (A), M44 (B), and gB (C) were detected by their reactivity with MAbs 
9D3.22A, 3B9.22A, and 2E8.21A+8G5.22A, respectively. The numbers to the right of panel 
A represent the sizes of pre-stained molecular weight markers in kiloDaltons. The 
recombinant MCMVs used were listed to the left of each panel. The different panels 
representing the Western blot analyses were prepared in Adobe Photoshop CS3. 
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4.2.3  Comparison of recombinant viral growth in different cell lines 
One of the ways I compared the recombinant viruses MCMV-ETwt, MCMV-ETSwa- 
and MCMV-EGFP was to analyze their growth properties by monitoring virus production in 
both permissive (Balb/3T3) and semi-permissive (COS-1) cells via plaque assays. These 
viruses were selected for analysis based on the rationale presented in section 4.1.1. In the 
permissive Balb/3T3 cell line, recombinant virus production was analyzed at both high and 
low MOI. During high MOI infections, the intention was to infect all the cells in a culture 
simultaneously. This ensured that the virus replication cycle was synchronized and data for a 
one-step growth curve could be analyzed. In contrast, during low MOI infection, only a small 
fraction of the total cell population was initially infected, and thus the ability of the virus to 
spread from cell to cell during infection could be monitored. In this instance, infected 
Balb/3T3 cells were monitored until most of the cells were destroyed by the virus spread over 
the course of infection. Finally, because growth of MCMV is abortive in COS-1 cells at low 
MOI, viral growth was only examined through high MOI infections. 
The overall trend of viral growth in Balb/3T3 cells at low MOI demonstrated that 
MCMV-EGFP, MCMV-ETwt and MCMV-ETSwa- all behaved very similarly to MCMV 
(Smith), the virus which served as the wild-type control (Figure 4.15). All four viruses showed 
similar growth kinetics with peak titers at 5 days post-infection of between 1.27 x 107 ± 1.41 x 
105 (MCMV-EGFP) and 1.68 x 107 ± 9.90 x 105 (MCMV-ETwt) PFU/106 cells. After this 
point, there was a slow drop in virus titers to between 2.16 x 106 ± 8.72 x 104 (MCMV-ETwt) 
and 4.05 x 106 ± 7.78 x 105 (MCMV-EGFP) PFU/106 cells. 
Comparison of viral growth at high MOI in Balb/3T3 cells also demonstrated that the 
four viruses had very similar growth kinetics (Figure 4.16). However, the virus titers varied to 
a greater extent than that observed during low MOI infection of Balb/3T3 cells. However, in 
plaque assays, a difference in virus titers of 2-3 fold is not very significant and is more likely 
to be due to normal experimental variations rather than real differences between the 
recombinant viruses themselves unless these differences can be demonstrated consistently over 
multiple experiments. Virus production peaked around 3 days post-infection for all 4 viruses. 
Overall, it would appear that during both high and low MOI infection in permissive cells, 
MCMV-ETwt and MCMV-ETSwa- both behaved very similarly to MCMV (Smith), indicating 
that the SwaI- mutation did not appear to have a significant effect on virus growth. Thus, the  
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Figure 4.15:  Replication of recombinant MCMVs in Balb/3T3 cells at low MOI 
Balb/3T3 cells were infected with either the Smith strain of MCMV, MCMV-EGFP, 
MCMV-ETwt, or MCMV-ETSwa- at a MOI of 0.1. Virus released into the media at 
appropriate times was quantified by plaque assays. Each data point was calculated as the 
mean of 2 to 4 determinations, with error bars representing the standard deviations. Some of 
the standard deviations are so small that the error bars are hidden beneath the symbols 
representing the data points. The legend for the recombinant viruses used is shown in the 
graph. 
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Figure 4.16:  Replication of recombinant MCMVs in Balb/3T3 cells at high MOI 
Balb/3T3 cells were infected with either the Smith strain of MCMV, MCMV-EGFP, 
MCMV-ETwt, or MCMV-ETSwa- at a MOI of 5. Virus released into the media at 
appropriate times was quantified by plaque assays. Each data point was calculated as the 
mean of 2 to 4 determinations, with error bars representing the standard deviations. Some of 
the standard deviations are so small that the error bars are hidden beneath the symbols 
representing the data points. The legend for the recombinant viruses used is shown in the 
graph. 
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phenotypes of both recombinant MCMVs resembled that of the Smith strain of MCMV. In 
addition, the growth of MCMV-EGFP was very similar to both MCMV-ETwt and MCMV 
(Smith) indicating that in permissive cells the insertion of the GFP cassette into mie2 does not 
appear to have a significant affect on viral growth kinetics. 
Virus growth at high MOI in COS-1 cells, a non-murine semi-permissive cell line, was 
also examined (Figure 4.17). Upon observation under the microscope, the number of cells 
showing cytopathic effects was significantly less than that observed in Balb/3T3 cells even 
when the same high MOI was used. All virus infections still followed the same pattern of the 
MCMV (Smith) strain, with an eclipse phase following the initial infection, virus titers that 
peaked at 3 days post-infection, and slowly declined throughout the infection after this point. 
Interestingly, the MCMV-EGFP virus had higher virus titers than the other 3 viruses, 
particularly between 4 and 5 days post-infection (Figure 4.17). This differed from observations 
made from similar experiments conducted previously in our laboratory. One plausible 
explanations for this observation is that the COS-1 cell line might have mutated during 
multiple cell passages. As a result, cells could become confluent much faster, at which point 
virus production would decrease rapidly. Therefore, in order to obtain results similar to those 
observed previously in this laboratory, a higher dosage of virus may be necessary, so that a 
larger percentage of COS-1 cells would exhibit cytopathic effects early in infection. 
The results of COS-1 infection indicated that the growth properties of MCMV-ETwt 
were similar to that of MCMV (Smith), and thus the “wild-type” phenotype of the virus 
appeared to have been restored. MCMV-ETSwa- also behaved very similarly to MCMV 
(Smith), indicating that the SwaI- mutation did not appear to have an affect on the growth 
properties of MCMV in COS-1 cells. 
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Figure 4.17:  Replication of recombinant MCMVs in COS-1 cells at high MOI 
COS-1 cells were infected with either the Smith strain of MCMV, MCMV-EGFP, MCMV-
ETwt, or MCMV-ETSwa- at a MOI of 5. Virus released into the media at appropriate times 
was quantified by plaque assays. Each data point was calculated as the mean of 2 to 4 
determinations, with error bars representing the standard deviations. Some of the standard 
deviations are so small that the error bars are hidden beneath the symbols representing the 
data points. The legend for the recombinant viruses used is shown in the graph. 
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5.0  DISCUSSION 
5.1  Feasibility of using a modified viral genome for the construction of recombinant 
murine cytomegaloviruses 
In this thesis, I have provided evidence that our method of constructing recombinant 
MCMV using a modified viral genome is viable and efficient.  This method is reliant upon the 
replacement of a specific region on the genome with a zeocin cassette flanked by SwaI sites 
(Figure 4.1), necessitating the removal of the unique SwaI site from the MCMV (Smith strain) 
genome. To this end, I constructed pMCMV_ETSwa-* which contained a single point 
mutation in the unique recognition sequence for SwaI. In addition, the GFP cassette in 
pMCMV_EGFP, which represented the start of our BAC construction lineage, was removed. 
Furthermore, I constructed pMCMV_ETwt where the mutated SwaI site in pMCMV_ETSwa-* 
was restored. The successful construction of this BAC using the aforementioned methodology 
demonstrated that after successful introduction of specific mutations into the viral genome, I 
could revert the mutated SwaI site in the EcoRI-T fragment of the MCMV genome to wild-
type sequences if the necessity arose (see sections 5.2 and 5.3). 
An advantage of our method of constructing viral recombinants is that co-
transformation of the linearized MCMV BAC genome with a mutated viral DNA fragment 
into a recombination competent E. coli strain such as DY380 results in efficient recovery of 
MCMV BACs incorporating the desired mutation via homologous recombination. This is due 
to the fact that bacterial transformation efficiency is much higher with circular rather than 
linear plasmids. Thus, upon homologous recombination, the re-circularized MCMV BACs 
containing the mutation will be recovered at higher frequencies than linearized BACs. Our 
experimental results support this prediction since the percentage of MCMV BAC clones that 
lost zeocin resistance, and thus presumably has incorporated the desired mutation, was fairly 
high (Table 4.2).  The initial screening for loss of zeocin resistance ensured that the number of 
recombinant clones that needed to be tested was manageable (Table 4.2). Subsequently, 
correct MCMV recombinants were identified by restriction analysis of MCMV BACs selected 
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for zeocin-sensitivity (Figures 4.5, 4.7-4.12). This analysis also allowed me to ascertain that no 
major rearrangements of the MCMV genome had occurred after the introduction of the desired 
mutations or alterations. In general 25% or higher of zeocin sensitive BAC clones had the 
correct profile (Table 4.2), indicating that our method of selecting recombinant BACs was 
quite efficient. 
Another potential advantage of our method of recombinant virus construction is that, 
unlike some of the approaches described in the introduction section, no foreign sequences are 
left at the site where the desired mutations are introduced. This may be important in studies on 
gene expression and DNA replication where sequences affecting promoters, enhancers, or 
origin of replication could be altered. 
5.2  Effect of the SwaI mutation on the biological properties of MCMV 
The biological properties of the recombinant MCMV-ETwt and MCMV-ETSwa- 
viruses and the standard Smith strain of MCMV were compared through analysis of viral DNA 
restriction patterns (Figure 4.13), protein expression (Figure 4.14), and viral growth curves in 
both permissive and semi-permissive cell lines (Figures 4.15-4.17). In so doing, I have 
provided preliminary evidence that the SwaI mutation did not appear to have an effect on 
selected biological properties of MCMV. Furthermore, the similarities between MCMV-ETwt 
and the Smith strain of MCMV suggested that our method of constructing recombinant 
MCMVs did not appear to result in unintentional alterations to the MCMV genome. However, 
since the experiments outlined in sections 4.2.1-4.2.3 have been carried out only once, they 
should be repeated to confirm the observations described in this thesis. 
5.3  Future experiments to analyze the effect of the SwaI mutation on the biological 
properties of MCMV 
Additional comparisons between MCMV-ETSwa-, MCMV-ETwt and the Smith strain 
of MCMV during infection of Balb/3T3 cells can be made by carrying out indirect 
immunofluorescence assays on infected cells with monoclonal antibodies specific for MCMV 
proteins expressed at different stages of the virus life cycle. These assays will be used to 
analyze the expression of immediate-early, early and late MCMV genes, the intracellular 
locations of these gene products, and the development of replication compartments at different 
times post-infection. Results from these experiments may provide additional evidence to 
support my aforementioned conclusions. 
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One of the assumptions that I made during my studies on infectious virus production is 
that MCMV released into the media is representative of total virus production during the virus 
life cycle. However, it is possible that the SwaI mutation could affect the release of MCMV 
into the media. Thus, it may be prudent to monitor the amount of cell-associated virus during 
infection by recombinant MCMVs before reaching a definitive conclusion. 
Although in vitro experiments described in this thesis have provided evidence to 
suggest that the SwaI mutation did not have an effect on selected biological properties of 
MCMV, further experimentation needs to be carried out to better evaluate the potential 
biological effects of this mutation in vivo. There are several examples of CMV genes that are 
conserved between different virus strains, but do not affect replication in permissive tissue 
culture cells. However, they are hypothesized to be required for successful in vivo infections. 
For example, in HCMV, both US3 and US11 genes play a role in immune evasion, a function 
not required in vitro (see section 1.2.4.2.2). Human CMV US10 and MCMV ie2, whose 
potential roles in the viral life cycle have not yet been determined (Manning and Mocarski, 
1988; Jones et al., 1991; Greaves et al., 1995), do not appear to be essential for infection of 
permissive cells in vitro. Although the point mutation introduced into the MCMV genome that 
destroyed the SwaI site did not interrupt any known genes, the possibility remains that it could 
disrupt an unknown control sequence, an intron, or an exon that is critical for successful in 
vivo infection. 
The biological effects of the SwaI mutation on in vivo MCMV infection can be 
determined by infecting Balb/C mice with the recombinant viruses MCMV-ETSwa-, MCMV-
ETwt, and the Smith strain of  MCMV. Virus infection can be monitored in the spleen, 
kidneys, lungs, and salivary glands by harvesting these organs and performing plaque assays 
as well as histochemical examinations of infected tissues. As our method of manipulating the 
viral genome did not appear to affect the biological properties of MCMV-ETwt in vitro, we 
expect that this virus would have a similar course of infection as the Smith strain of MCMV.  
If results from these experiments with mice infected with MCMV-ETSwa- and the Smith strain 
of MCMV differ significantly, the SwaI site will need to be restored following future 
manipulations of the MCMV genome. I have already demonstrated this that is possible 
through the construction of pMCMV_ETwt. The results of these in vivo studies will provide 
more conclusive evidence regarding the biological effects of the SwaI mutation. 
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5.4  Utility of the SwaI- MCMV backbone to future research in our laboratory 
Once in vivo testing is completed to ensure that there are no obvious biological effects 
due to the SwaI mutation, the pMCMV_ETSwa-* backbone will be very useful for the 
construction of recombinant MCMV. This will enable the construction of recombinant MCMV 
with specific alterations/mutations in any region of the viral genome. Alternatively, chimeric 
viruses where MCMV coding sequences are replaced by those from corresponding HCMV 
homologs can be constructed to investigate the mechanisms of host specificity or facilitate the 
testing of anti-HCMV therapies. 
As a specific example of this, the pMCMV_ETSwa-*/ie1SwaZeo BAC (section 
4.1.2.7) can be used to construct a mie1 null mutant containing a stop codon at the beginning 
of exon 4, which is unique to this gene. In addition, the mie1 exon 4 sequences could be 
replaced with the corresponding sequences from HCMV ie1. We shall leave the splicing 
signals intact so that the structures of immediate-early transcripts would not be altered. The 
resultant recombinant MCMVs could be used to investigate the role of mie1 in host specificity 
by monitoring infection and gene expression in murine and human cells.  The 
pMCMV_ETSwa-*/ie1SwaZeo BAC could also be used to incorporate specific mutations into 
mie1 or HCMV ie1 sequences that are required for interactions with cellular proteins such as 
PML, DAXX, and HDAC, and facilitate the mapping of functional domains that may be 
involved in these interactions. Thus, their effects on cytomegalovirus host specificity can be 
evaluated.
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